MariMed (MRMD) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 16, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	0-54433
Entity Registrant Name	MARIMED INC.
Entity Central Index Key	0001522767
Entity Tax Identification Number	27-4672745
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10 Oceana Way
Entity Address, City or Town	Norwood
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02062
City Area Code	617
Local Phone Number	795-5140
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		329,143,662

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 17,356,525	$ 2,999,053
Accounts receivable, net	8,085,867	6,675,512
Deferred rents receivable	1,815,330	1,940,181
Notes receivable, current portion	377,127	658,122
Inventory	9,228,098	6,830,571
Investments	941,910	1,357,193
Other current assets	1,955,445	582,589
Total current assets	39,760,302	21,043,221
Property and equipment, net	52,666,031	45,636,529
Intangibles, net	2,521,094	2,228,560
Investments	1,165,788	1,165,788
Notes receivable, less current portion	1,194,448	965,008
Right-of-use assets under operating leases	5,406,601	5,247,152
Right-of-use assets under finance leases	62,078	78,420
Other assets	97,950	80,493
Total assets	102,874,292	76,445,171
Current liabilities:
Accounts payable	6,693,390	5,044,918
Accrued expenses	8,145,061	3,621,269
Sales and excise taxes payable	1,535,226	1,053,693
Debentures payable		1,032,448
Notes payable, current portion	9,523	8,859,175
Mortgages payable, current portion	1,350,548	1,387,014
Operating lease liabilities, current portion	1,118,121	1,008,227
Finance lease liabilities, current portion	33,453	38,412
Due to related parties		1,157,815
Other current liabilities		23,640
Total current liabilities	18,885,322	23,226,611
Notes payable, less current portion	2,015,001	10,682,234
Mortgages payable, less current portion	14,484,255	14,744,136
Operating lease liabilities, less current portion	4,862,628	4,822,064
Finance lease liabilities, less current portion	33,098	44,490
Other liabilities	100,200	100,200
Total liabilities	40,380,504	53,619,735
Mezzanine equity:
Total mezzanine equity	37,725,000	14,725,000
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value; 38,875,451 and 45,091,667 shares authorized at June 30, 2021 and December 31, 2020, respectively; zero shares issued and outstanding at June 30, 2021 and December 31, 2020
Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2021 and December 31, 2020; 326,838,535 and 314,418,812 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	326,839	314,419
Common stock subscribed but not issued; zero and 11,413 shares at June 30, 2021 and December 31, 2020, respectively		5,365
Additional paid-in capital	117,919,783	112,974,329
Accumulated deficit	(92,903,783)	(104,616,538)
Noncontrolling interests	(574,051)	(577,139)
Total stockholders’ equity	24,768,788	8,100,436
Total liabilities, mezzanine equity, and stockholders’ equity	102,874,292	76,445,171
Series B Convertible Preferred Stock [Member]
Mezzanine equity:
Total mezzanine equity	14,725,000	14,725,000
Series C Convertible Preferred Stock [Member]
Mezzanine equity:
Total mezzanine equity	$ 23,000,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	38,875,451	45,091,667
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	326,838,535	314,418,812
Common stock, shares outstanding	326,838,535	314,418,812
Common stock, shares subscribed but unissued	0	11,413
Series B Convertible Preferred Stock [Member]
Mezzanine equity, par value	$ 0.001	$ 0.001
Mezzanine equity, shares authorized	4,908,333	4,908,333
Mezzanine equity, shares issued	4,908,333	4,908,333
Mezzanine equity, shares outstanding	4,908,333	4,908,333
Series C Convertible Preferred Stock [Member]
Mezzanine equity, par value	$ 0.001	$ 0.001
Mezzanine equity, shares authorized	6,216,216	0
Mezzanine equity, shares issued	6,216,216	0
Mezzanine equity, shares outstanding	6,216,216	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 32,569,656	$ 9,610,306	$ 57,212,220	$ 17,076,325
Cost of revenues	13,163,306	3,452,169	24,619,952	6,050,086
Gross profit	19,406,350	6,158,137	32,592,268	11,026,239
Operating expenses:
Personnel	2,058,254	1,207,141	3,785,395	2,720,524
Marketing and promotion	270,330	65,618	494,699	178,002
General and administrative	4,282,004	2,336,102	7,452,728	4,584,037
Bad debts	793,871	450,000	1,819,286	450,000
Total operating expenses	7,404,459	4,058,861	13,552,108	7,932,563
Operating income	12,001,891	2,099,276	19,040,160	3,093,676
Non-operating income (expenses):
Interest expense	(264,596)	(2,969,191)	(1,776,618)	(5,660,336)
Interest income	35,768	40,863	69,795	86,894
Loss on obligations settled with equity	(1,260)	(44,678)	(2,546)	(44,678)
Loss on equity investments		(32,958)		(32,958)
Change in fair value of investments	(370,119)	(234,544)	(415,284)	(921,546)
Total non-operating income (expenses), net	(600,207)	(3,240,508)	(2,124,653)	(6,572,624)
Income (loss) before income taxes	11,401,684	(1,141,232)	16,915,507	(3,478,948)
Provision for income taxes	3,813,108		5,016,905
Net income (loss)	7,588,576	(1,141,232)	11,898,602	(3,478,948)
Net income (loss) attributable to noncontrolling interests	95,724	72,805	185,847	156,533
Net income (loss) attributable to MariMed Inc.	$ 7,492,852	$ (1,214,037)	$ 11,712,755	$ (3,635,481)
Net income (loss) per share
Basic	$ 0.02	$ 0	$ 0.04	$ (0.02)
Diluted	$ 0.02	$ 0	$ 0.03	$ (0.02)
Weighted average common shares outstanding
Basic	324,266,644	247,990,403	321,740,575	240,664,873
Diluted	370,256,963	247,990,403	365,323,638	240,664,873

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Common Stock Subscribed But Not Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2019	$ 228,408	$ 1,168,074	$ 112,245,730	$ (106,760,527)	$ (553,465)	$ 6,328,220
Balances, shares at Dec. 31, 2019	228,408,024	3,236,857
Issuance of subscribed shares	$ 3,237	$ (1,168,074)	1,164,837
Issuance of subscribed shares, shares	3,236,857	(3,236,857)
Stock grants	$ 30	$ 5,365	5,335			10,730
Stock grants, shares	30,307	34,171
Amortization of option grants			556,379			556,379
Issuance of warrants attached to debt			65,931			65,931
Discount on debentures payable			28,021			28,021
Beneficial conversion feature on debentures payable			379,183			379,183
Conversion of debentures payable	$ 35,887		4,981,208			5,017,095
Conversion of debentures payable, shares	35,886,796
Conversion of common stock to preferred stock	$ (4,908)		(14,720,092)			(14,725,000)
Conversion of common stock to preferred stock, shares	(4,908,333)
Conversion of promissory notes	$ 2,525		457,525			460,050
Conversion of promissory notes, shares	2,525,596
Extinguishment of promissory note	$ 1,900		350,100			352,000
Extinguishment of promissory note, shares	1,900,000
Common stock issued to settle obligations	$ 4,400		739,200			743,600
Common stock issued to settle obligations, shares	4,400,000
Distributions					(166,952)	(166,952)
Net income				(3,635,481)	156,533	(3,478,948)
Balance at Jun. 30, 2020	$ 271,479	$ 5,365	106,253,357	(110,396,008)	(563,884)	(4,429,691)
Balances, shares at Jun. 30, 2020	271,479,247	34,171
Balance at Dec. 31, 2019	$ 228,408	$ 1,168,074	112,245,730	(106,760,527)	(553,465)	6,328,220
Balances, shares at Dec. 31, 2019	228,408,024	3,236,857
Balance at Dec. 31, 2020	$ 314,419	$ 5,365	112,974,329	(104,616,538)	(577,139)	8,100,436
Balances, shares at Dec. 31, 2020	314,418,812	11,413
Issuance of subscribed shares	$ 11	$ (5,365)	5,354
Issuance of subscribed shares, shares	11,413	(11,413)
Stock grants	$ 7		5,358			5,365
Stock grants, shares	6,877
Amortization of option grants			884,075			884,075
Conversion of debentures payable	$ 4,611		1,351,841			1,356,452
Conversion of debentures payable, shares	4,610,645
Conversion of promissory notes	$ 6,937		2,252,854			2,259,791
Conversion of promissory notes, shares	6,937,400
Extinguishment of promissory note
Common stock issued to settle obligations	$ 72		53,473			53,545
Common stock issued to settle obligations, shares	71,691
Distributions					(182,759)	(182,759)
Exercise of options	$ 83		8,917			9,000
Exercise of options, share	82,885
Exercise of warrants	$ 699		60,098			60,797
Exercise of warrants, shares	698,812
Issuance of stand-alone warrants			55,786			55,786
Issuance of warrants with stock			654,681			654,681
Equity issuance costs			(386,983)			(386,983)
Net income				11,712,755	185,847	11,898,602
Balance at Jun. 30, 2021	$ 326,839		$ 117,919,783	$ (92,903,783)	$ (574,051)	$ 24,768,788
Balances, shares at Jun. 30, 2021	326,838,535

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Cash flows from operating activities:
Net income (loss) attributable to MariMed Inc.	$ 7,492,852	$ (1,214,037)	$ 11,712,755	$ (3,635,481)
Net income (loss) attributable to noncontrolling interests	95,724	72,805	185,847	156,533
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation			962,571	907,285
Amortization of intangibles			346,036	166,908
Amortization of stock grants			5,365	10,730
Amortization of option grants			884,075	556,379
Amortization of stand-alone warrant issuances			55,786
Amortization of warrants attached to debt			539,272	498,694
Amortization of warrants issued with stock			654,681
Amortization of beneficial conversion feature			176,522	2,170,401
Amortization of original issue discount			51,753	241,613
Bad debt expense	793,871	450,000	1,819,286	450,000
Loss on obligations settled with equity			2,546	44,678
Equity in earnings of investments				32,958
Change in fair value of investments	370,119	234,544	415,284	921,546
Changes in operating assets and liabilities:
Accounts receivable, net			(3,229,641)	(1,654,366)
Deferred rents receivable			124,851	(193,464)
Inventory			(2,397,527)	(2,686,534)
Other current assets			(1,372,856)	(215,413)
Other assets			(17,458)	(10,000)
Accounts payable			1,699,471	566,749
Accrued expenses			4,522,782	1,363,094
Sales and excise taxes payable			481,533	396,236
Operating lease payments, net			(8,991)	51,043
Finance lease interest payments			1,504	4,033
Other current liabilities			(23,640)	396,236
Net cash provided by operating activities			17,591,807	539,858
Cash flows from investing activities:
Purchase of property and equipment			(7,975,731)	(2,720,655)
Purchase of cannabis licenses			(638,570)	(255,000)
Interest on notes receivable			118,811	406,670
Net cash used in investing activities			(8,495,490)	(2,568,985)
Cash flows from financing activities:
Proceeds from issuance of preferred stock			23,000,000
Equity issuance costs			(386,983)
Proceeds from issuance of promissory notes			35,096	5,249,763
Repayments of promissory notes			(15,801,979)	(3,100,000)
Proceeds from issuance of debentures				935,000
Proceeds from mortgages				907,200
Payments on mortgages			(296,347)	(112,352)
Proceeds from exercise of options			9,000
Proceeds from exercise of warrants			60,797
Due to related parties			(1,157,815)	(63,404)
Finance lease principal payments			(17,855)	(19,206)
Distributions			(182,759)	(166,952)
Net cash provided by financing activities			5,261,155	3,630,049
Net change to cash and cash equivalents			14,357,472	1,600,922
Cash and cash equivalents at beginning of period			2,999,053	738,688	$ 738,688
Cash and cash equivalents at end of period	$ 17,356,525	$ 2,339,610	17,356,525	2,339,610	$ 2,999,053
Supplemental disclosure of cash flow information:
Cash paid for interest			1,405,489	703,571
Cash paid for income taxes			419,003	13,000
Non-cash activities:
Conversion of promissory notes			2,259,791	460,050
Conversions of debentures payable			1,356,452	5,017,095
Operating lease right-of-use assets and liabilities			466,105
Common stock issued to settle obligations			51,000	698,922
Issuance of common stock associated with subscriptions			5,365	1,168,074
Cashless exercise of warrants			180
Cashless exercise of stock options			53
Exchange of common stock to preferred stock				14,725,000
Conversion of accrued interest to promissory notes				3,908,654
Beneficial conversion feature on debentures payable				379,183
Extinguishment of promissory note				352,000
Discount on promissory notes				65,931
Discount on debentures payable				$ 28,021

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS MariMed Inc. (the “Company”) is a multi-state operator in the United States cannabis industry. The Company develops, operates, manages, and optimizes over 300,000 Upon its entry into the cannabis industry in 2014, the Company was an advisory firm that procured state-issued cannabis licenses on behalf of its clients, developed cannabis facilities which it leased to these newly-licensed companies, and provided industry-leading expertise and oversight in all aspects of their cannabis operations. The Company also provided its clients with as ongoing regulatory, accounting, real estate, human resources, and administrative services. Thereafter , the Company made the strategic decision to transition from a consulting business to a direct owner and operator of cannabis licenses in high-growth states. Core to this transition is the acquisition and consolidation of the Company’s clients (the “Consolidation Plan”). Among several benefits, the Consolidation Plan would present a simpler, more transparent financial picture of the full breadth of the Company’s efforts, with a clearer representation of the revenues, earnings, and other financial metrics the Company has generated for its clients. The Company has played a key role in the successes of these entities, from the securing of their cannabis licenses, to the development of facilities that are models of excellence, to funding their operations, and to providing operational and corporate guidance. Accordingly, the Company believes it is well suited to own these facilities and manage the continuing growth of their operations. To date, acquisitions of its client businesses in Massachusetts and Illinois have been completed and establish the Company as a fully integrated seed-to-sale multi-state operator (“MSO”). The acquisitions of the remaining entities located in Maryland, Nevada, and Delaware are at various stages of completion and subject to each state’s laws governing the ownership transfer of cannabis licenses, which in the case of Delaware requires a modification of current cannabis ownership laws to permit for-profit ownership. Meanwhile, the Company continues to expand these businesses and maximize the Company’s revenue from rental income, management fees, and licensing royalties. The transition to becoming a fully integrated MSO is part of a strategic growth plan (the “Strategic Growth Plan”) the Company is implementing to drive its revenues and profitability. The Strategic Growth Plan has four components: (i) complete the Consolidation Plan, (ii) increase revenues in existing states, by spending capital to increase the Company’s cultivation and production capacity, and develop additional assets within those states, (iii) expand the Company’s footprint in additional legal cannabis states through new applications and acquisitions of existing cannabis businesses; and (iv) expand the Company’s brand portfolio and licensing revenue, by continuing to build its portfolio of leading brands and license its brands in other legal states. As to its products, the Company has created its own brands of cannabis flower, concentrates, and precision-dosed products utilizing proprietary strains and formulations. These products are developed by the Company in cooperation with state-licensed operators who meet the Company’s strict standards, including all natural—not artificial or synthetic—ingredients. The Company licenses its brands and product formulations only to certified manufacturing professionals who follow state cannabis laws and adhere to the Company’s precise scientific formulations and trademarked product recipes. The Company’s proprietary cannabis genetics produce flowers and concentrates under the brand name Nature’s Heritage™, and cannabis-infused products under the brand names Kalm Fusion®, in the form of chewable tablets and drink powder mixes, and the award-winning 1 2 The Company also has exclusive sublicensing rights in certain states to distribute the Binske® line of cannabis products crafted from premium artisan ingredients, the Healer™ line of medical full-spectrum cannabis tinctures, and the clinically tested medicinal cannabis strains developed in Israel by global medical cannabis research pioneer Tikun Olam™. The Company intends to continue licensing and distributing its brands as well as other top brands in the Company’s current markets. The Company’s stock is quoted on the OTCQX market under the ticker symbol MRMD. The Company was incorporated in Delaware in January 2011 under the name Worlds Online Inc. Initially, the Company developed and managed online virtual worlds. By early 2014, this line of business effectively ceased operating, and the Company pivoted into the legal cannabis industry. 1 2

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In accordance with GAAP, interim financial statements are not required to contain all of the disclosures normally required in annual financial statements. In addition, the results of operations of interim periods may not necessarily be indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s most recent audited annual financial statements and accompanying notes for the year ended December 31, 2020. Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries at June 30, 2021: SCHEDULE OF MAJORITY OWNED SUBSIDIARIES Subsidiary: Percentage MariMed Advisors Inc. 100.0% Mia Development LLC 89.5% Mari Holdings IL LLC 100.0% Mari Holdings MD LLC 97.4% Mari Holdings NV LLC 100.0% Mari Holdings Metropolis LLC 100.0% Mari Holdings Mt. Vernon LLC 100.0% Hartwell Realty Holdings LLC 100.0% iRollie LLC 100.0% ARL Healthcare Inc. 100.0% KPG of Anna LLC 100.0% KPG of Harrisburg LLC 100.0% MariMed Hemp Inc. 100.0% MediTaurus LLC 70.0% Intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions. Cash Equivalents The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values. The Company’s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the normal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard. Accounts Receivable Accounts receivable consist of trade receivables and are carried at their estimated collectible amounts. The Company provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding balances with consideration towards such client’s historical collection experience, as well as prevailing economic and market conditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $41.4 million and $40.0 million at June 30, 2021 and December 31, 2020, respectively. Please refer to Note 17 – Bad Debts Inventory Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard criteria. The Company reviews physical inventory for obsolescence and/or excess and will record a write-down if necessary. Investments Investments are comprised of equity holdings in private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments are deemed to have occurred. Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract with Customers, ● Identify the contract(s) with a customer; ● Identify the performance obligations in the contract(s); ● Determine the transaction price; ● Allocate the transaction price to the performance obligations in the contract(s); and ● Recognize revenue as the performance obligation is satisfied. Additionally, when another party is involved in providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other party—is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging for goods or services to be provided by the other party. The Company is typically considered the principal if it controls the specified good or service before such good or service is transferred to its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations and risks, (ii) possesses certain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance obligations it does not satisfy. The Company’s main sources of revenue are comprised of the following: ● Product Sales – direct sales of cannabis and cannabis-infused products by the Company’s retail dispensaries and wholesale operations in Massachusetts and Illinois, and sales of hemp and hemp-infused products. An increase in product sales is expected from the Company’s planned cannabis-licensee acquisitions in Maryland, Nevada, and Delaware (upon this state’s amendment to permit for-profit ownership of cannabis entities). This revenue is recognized when products are delivered or at retail points-of-sale. ● Real Estate – rental income and additional rental fees generated from leasing of the Company’s state-of-the-art, regulatory-compliant cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed specified amounts. ● Management – fees for providing the Company’s cannabis clients with comprehensive oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue and are recognized after services have been performed. ● Supply Procurement – the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies, and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser. ● Licensing – royalties from the licensed distribution of the Company’s branded products including Kalm Fusion® and Betty’s Eddies®, and from sublicensing of contracted brands including Healer and Tikun Olam, to regulated dispensaries throughout the United States and Puerto Rico. The recognition of this revenue occurs when the products are delivered. Research and Development Costs Research and development costs are charged to operations as incurred. Property and Equipment Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred. The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, forty years the remaining duration of the related lease seven ten ten years The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment loss is measured by the excess of the asset’s carrying amount over its estimated fair value. Impairment analyses are based on management’s current plans, asset holding periods, and currently available market information. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements. For the six months ended June 30, 2021 and 2020, based on the results of management’s impairment analyses, there were no impairment losses. Leases The consolidated financial statements reflect the Company’s adoption of ASC 842, Leases ASC 842 is intended to improve financial reporting of leasing transactions. The most prominent change from previous accounting guidance is the requirement to recognize right-of-use assets and lease liabilities on the consolidated balance sheet representing the rights and obligations created by operating leases that extend more than twelve months in which the Company is the lessee. The Company elected the package of practical expedients permitted under ASC 842. Accordingly, the Company accounted for its existing operating leases that commenced before the effective date as operating leases under the new guidance without reassessing (i) whether the contracts contain a lease, (ii) the classification of the leases (iii) the accounting for indirect costs as defined in ASC 842. The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Non-lease components within lease agreements are accounted for separately. Right-of-use assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Impairment of Long-Lived Assets The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets Fair Value of Financial Instruments The Company follows the provisions of ASC 820, Fair Value Measurement Financial Instruments, Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable, approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by the Company during the six months ended June 30, 2021 and 2020: SCHEDULE OF ASSUMPTIONS USED Six Months Ended June 30, 2021 2020 Life of instrument 3.0 5.0 3.0 Volatility factors 1.230 1.266 1.059 1.180 Risk-free interest rates 0.36 0.90% 0.33 1.33% Dividend yield 0 0% The expected life of an instrument is calculated using the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based Payment The Company amortizes the fair value of option and warrant issuances on a straight-line basis over the requisite service period of each instrument. Extinguishment of Liabilities The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation, Income Taxes The Company uses the asset and liability method to account for income taxes in accordance with ASC 740, Income Taxes ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no Related Party Transactions The Company follows ASC 850, Related Party Disclosures In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements. Comprehensive Income The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income Earnings Per Share Earnings per common share is computed pursuant to ASC 260, Earnings Per Share As of June 30, 2021 and 2020, there were potentially dilutive securities convertible into shares of common stock comprised of (i) stock options – convertible into 12,402,750 6,805,750 29,174,958 12,710,107 4,908,333 31,081,080 zero zero 46,410,593 5,605,260 29,421,133 For the three and six months ended June 30, 2021, the aforementioned potentially dilutive securities increased the number of weighted average common shares outstanding on a diluted basis by 45,990,319 shares and 43,583,063 shares, respectively, in accordance with ASC 260, and are included in the calculation of diluted net income per share for such periods. For the three and six months ended June 30, 2020, the potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculations, resulting in identical basic and fully diluted net income per share for that period. Commitments and Contingencies The Company follows ASC 450, Contingencies If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows. Beneficial Conversion Features on Convertible Debt Convertible instruments that are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging A beneficial conversion feature is a nondetachable conversion feature that is “in-the-money” at the commitment date. The in-the-money portion, also known as the intrinsic value, is recorded in equity, with an offsetting discount to the carrying amount of convertible debt to which it is attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization upon full or partial conversions of the debt. Risk and Uncertainties The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws. Noncontrolling Interests Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets. Off Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements.

ACQUISITIONS

ACQUISITIONS	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS	NOTE 3 – ACQUISITIONS The Harvest Foundation LLC In August 2019, the Company entered into a purchase agreement to acquire 100% The purchase price is comprised of the issuance of (i) 1,000,000 1.2 400,000 Kind Therapeutics USA Inc. In the fall of 2016, the members of Kind Therapeutics USA Inc., the Company’s cannabis-licensed client in Maryland that holds licenses for the cultivation, production, and dispensing of medical cannabis (“Kind”), and the Company agreed to a partnership/joint venture whereby Kind would be owned 70% 30% 100% $6.3 2,500,000 Also in December 2018, (i) MariMed Advisors Inc., the Company’s wholly owned subsidiary, and Kind entered into a management services agreement to provide Kind with comprehensive management services in connection with the business and operations of Kind (“the MSA”), and (ii) Mari Holdings MD LLC, the Company’s majority-owned subsidiary, entered into a 20 180,000 9,000 In 2019, the members of Kind sought to renegotiate the terms of the MOU and have subsequently sought to renege on both the original partnership/joint venture and the MOU. The Company engaged with Kind in good faith in an attempt to reach updated terms acceptable to both parties, however Kind failed to reciprocate in good faith, resulting in an impasse. Incrementally, both parties through counsel further sought to resolve the impasse, however such initiative resulted in both parties commencing legal proceedings. As a result, the consummation of this acquisition has been delayed and may not ultimately be completed. The litigation is further discussed in Note 19 – Commitments and Contingencies MediTaurus LLC In 2019, the Company acquired a 70 % ownership interest in MediTaurus LLC (“MediTaurus”), a company formed by Jokubas Ziburkas PhD, a neuroscientist and leading authority on cannabidiol (“CBD”) and the endocannabinoid system, in exchange for $ 2.8 million of cash and stock. The Company currently sells CBD products developed by MediTaurus under its Florance™ brand, and expects to acquire the remaining 30% of MediTaurus in 2021.

INVESTMENTS

INVESTMENTS	6 Months Ended
	Jun. 30, 2021
Schedule of Investments [Abstract]
INVESTMENTS	NOTE 4 – INVESTMENTS At June 30, 2021 and December 31, 2020, the Company’s investments were comprised of the following: SCHEDULE OF INVESTMENTS June 30, December 31, Current investments: Flowr Corp. (formerly Terrace Inc.) $ 941,910 $ 1,357,193 Non-current investments: MembersRSVP LLC 1,165,788 1,165,788 Total investments $ 2,107,698 $ 2,522,981 Flowr Corp. (formerly Terrace Inc.) In December 2020, Terrace Inc., a Canadian cannabis entity in which the Company had an ownership interest of 8.95% 0.4973 This investment is carried at it fair value. During the six months ended June 30, 2021 and 2020, the decrease in fair value of this investment of approximately $415,000 and $664,000 , respectively, was reflected in Change In Fair Value Of Investments MembersRSVP LLC In August 2018, the Company invested $300,000 378,259 $915,000 23% During the six months ended June 30, 2020, the investment was accounted for under the equity method. Based on the Company’s equity in MRSVP’s net loss during such period, the Company recorded a charge of approximately $ 33,000 which comprised the balance of Loss on Equity Investments In January 2021, the Company and MRSVP entered into an agreement whereby the Company assigned and transferred membership interests comprising an 11% 12% As part of the agreement, the Company relinquished its right to appoint a member to the board of MRSVP. In light of the Company no longer having the ability to exercise significant influence over MRSVP, the Company discontinued accounting for this investment under the equity method as of January 1, 2021. The Company’s share of MRSVP’s earnings and losses recorded under the equity method prior to January 1, 2020 will remain part of the carrying amount of the investment. In accordance with ASC 321, Investments – Equity Securities The Company will continue to apply the alternative measurement guidance until this investment does not qualify to be so measured. The Company may subsequently elect to measure this investment at fair value, with changes in fair value recognized in net income.

DEFERRED RENTS RECEIVABLE

DEFERRED RENTS RECEIVABLE	6 Months Ended
	Jun. 30, 2021
Deferred Rents Receivable
DEFERRED RENTS RECEIVABLE	NOTE 5 – DEFERRED RENTS RECEIVABLE The Company is the lessor under operating leases which contain rent holidays, escalating rents over time, options to renew, requirements to pay property taxes, insurance and/or maintenance costs, and contingent rental payments based on a percentage of monthly tenant revenues. The Company is not the lessor under any finance leases. The Company recognizes fixed rental receipts from such lease agreements on a straight-line basis over the expected lease term. Differences between amounts received and amounts recognized are recorded under Deferred Rents Receivable The Company leases the following owned properties: ● Delaware – a 45,000 expires in 2035 ● Maryland – a 180,000 expires in 2037 ● Massachusetts – a 138,000 expires in 2022 The Company subleases the following properties: ● Delaware – 4,000 lease expiring in December 2021 with a five-year option to extend ● Delaware – a 100,000 The lease expires in March 2030, with an option to extend the term for three additional five-year periods ● Delaware – a 12,000 The lease expires in January 2026 and contains an option to negotiate an extension at the end of the lease term As of June 30, 2021 and December 31, 2020, cumulative fixed rental receipts under such leases approximated $16.3 million and $13.9 million, respectively, compared to revenue recognized on a straight-line basis of approximately $18.1 million and $15.8 million, respectively. Accordingly, the deferred rents receivable balance approximated $ 1.8 million and $1.9 million at June 30, 2021 and December 31, 2020, respectively. Future minimum rental receipts for non-cancelable leases and subleases as of June 30, 2021 were: SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON-CANCELABLE LEASES AND SUBLEASES 2021 2021 $ 2,411,711 2022 4,740,130 2023 4,446,410 2024 4,506,585 2025 4,574,023 Thereafter 39,591,553 Total $ 60,270,412

NOTES RECEIVABLE

NOTES RECEIVABLE	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
NOTES RECEIVABLE	NOTE 6 – NOTES RECEIVABLE At June 30, 2021 and December 31, 2020, notes receivable, including accrued interest, consisted of the following: SCHEDULE OF NOTES RECEIVABLE June 30, December 31, First State Compassion Center $ 437,014 $ 468,985 Healer LLC 879,642 899,226 High Fidelity Inc. 254,919 254,919 Total notes receivable 1,571,575 1,623,130 Notes receivable, current portion 377,127 658,122 Notes receivable, less current portion $ 1,194,448 $ 965,008 First State Compassion Center The Company’s cannabis-licensed client in Delaware, First State Compassion Center, issued a 10 -year promissory note to the Company in May 2016 in the amount of $700,000 bearing interest at a rate of 12.5% per annum, as amended. The monthly payments of approximately $10,000 will continue through April 2026, at which time the note will be fully paid down. At June 30, 2021 and December 31, 2020, the current portion of this note approximated $70,000 and $66,000 , respectively, and was included in Notes Receivable, Current Portion Healer LLC In 2018 and 2019, the Company loaned an aggregate of $800,000 6% In March 2021, the Company was issued a revised promissory note from Healer in the principal amount of approximately $894,000 6% requires quarterly payments of interest from April 2021 through the maturity date in April 2026 Additionally, the Company has the right to offset any licensing fees owed to Healer by the Company in the event Healer fails to make any timely payment. In March 2021, the Company offset approximately $28,000 $866,000 At June 30, 2021 and December 30, 2020, the total amount of principal and accrued interest due under the aforementioned promissory notes approximated $880,000 and $899,000 , respectively, of which approximately $52,000 and $337,000, respectively, was current. High Fidelity In August 2019, the Company loaned $250,000 to High Fidelity Inc., an entity that owns and operates two seed-to sale medical marijuana facilities in the state of Vermont and produces its own line of CBD products. The loan bore interest at a rate of 10.0% per annum, and was repaid in full in August 2021. Maryland Health & Wellness Center Inc. In 2019, the Company provided Maryland Health & Wellness Center Inc. (“MHWC”), an entity that has been pre-approved by the state of Maryland for a cannabis dispensing license, with a $300,000 8%

INVENTORY

INVENTORY	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
INVENTORY	NOTE 7 – INVENTORY At June 30, 2021 and December 31, 2020, inventory was comprised of the following: SCHEDULE OF INVENTORY June 30, December 31, Plants $ 3,570,394 $ 3,352,425 Ingredients and other raw materials 245,353 176,338 Work-in-process 326,095 468,377 Finished goods 5,086,256 2,833,431 Total inventory $ 9,228,098 $ 6,830,571

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 8 – PROPERTY AND EQUIPMENT At June 30, 2021 and December 31, 2020, property and equipment consisted of the following: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, December 31, Land $ 3,988,810 $ 3,988,810 Buildings and building improvements 31,187,512 29,309,856 Tenant improvements 9,044,543 8,844,974 Furniture and fixtures 796,742 619,880 Machinery and equipment 6,058,423 4,620,924 Construction in progress 7,424,950 3,140,807 58,500,981 50,525,251 Less: accumulated depreciation (5,834,949 ) (4,888,722 ) Property and equipment, net $ 52,666,031 $ 45,636,529 During the six months ended June 30, 2021 and December 31, 2020, additions to property and equipment approximated $7,976,000 and $1,876,000 , respectively. The 2021 additions were primarily comprised of (i) the development of facilities in Milford, DE and Metropolis, IL, and (ii) purchases of building improvements, machinery, and equipment at the facilities in Middleboro, MA and New Bedford, MA. The 2020 additions consisted primarily of (i) the development of the facility in Mt. Vernon, IL, and (ii) improvements to facilities in Anna, IL and Harrisburg, IL. The construction in progress balances of approximately $7.4 million and $3.1 million at June 30, 2021 and December 31, 2020, respectively, consisted of the commencement of construction of properties in Milford, DE and Annapolis, MD. Depreciation expense for the six months ended June 30, 2021 and 2020 approximated $963,000 and $907,000 , respectively.

INTANGIBLES

INTANGIBLES	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 9 – INTANGIBLES At June 30, 2021 and December 31, 2020, intangible assets were comprised of (i) the carrying value of cannabis license fees, and (ii) goodwill arising from the Company’s acquisitions. The Company’s cannabis licenses are issued from the states of Illinois and Massachusetts and require the payment of annual fees. These fees, comprised of a fixed component and a variable component based on the level of operations, are capitalized and amortized over the respective twelve-month periods. At June 30, 2021 and December 31, 2020, the carrying value of these cannabis licenses approximated $453,000 and $161,000 , respectively. The goodwill associated with acquisitions is reviewed on a quarterly basis for impairment. Based on this review and other factors, the goodwill of approximately $2.1

DEBT

DEBT	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
DEBT	NOTE 10 – DEBT Mortgages Payable At June 30, 2021 and December 31, 2020, mortgage balances, including accrued interest, were comprised of the following: SCHEDULE OF MORTGAGES PAYABLE June 30, December 31, Bank of New England – Massachusetts properties $ 12,665,790 $ 12,834,090 Bank of New England – Delaware property 1,519,716 1,575,658 DuQuoin State Bank – Illinois properties 793,733 814,749 South Porte Bank – Illinois property 855,564 906,653 Total mortgages payable 15,834,803 16,131,150 Mortgages payable, current portion (1,350,548 ) (1,387,014 ) Mortgages payable, less current portion $ 14,484,255 $ 14,744,136 In November 2017, the Company entered into a 10 -year mortgage agreement with Bank of New England in the amount of $4,895,000 (the “Initial Mortgage”) for the purchase of a 138,000 square foot industrial property in New Bedford, Massachusetts, within which the Company has built a 70,000 square foot cannabis cultivation and processing facility. Pursuant to the Initial Mortgage, the Company made monthly payments of (i) interest-only from the mortgage date through May 2019 at a rate equal to the prime rate plus 2% , with a floor of 6.25% per annum, and (ii) principal and interest payments from May 2019 to July 2020 at a rate equal to the prime rate on May 2, 2019 plus 2% , with a floor of 6.25% per annum. In July 2020, at which time the Initial Mortgage had a remaining principal balance of approximately $4.8 million, the parties consummated an amended and restated mortgage agreement, secured by the Company’s properties in New Bedford and Middleboro in the amount of $13.0 million bearing interest at a rate of 6.5% per annum that matures in August 2025 (the “Refinanced Mortgage”). Proceeds from the Refinanced Mortgage were used to pay down the Initial Mortgage and approximately $7.2 million of promissory notes as further described below. At June 30, 2021 and December 31, 2020, the outstanding principal balance of the Refinanced Mortgage approximated $12.7 million and $ 12.8 million, respectively, of which approximately $346,000 and $335,000 , respectively, was current. The Company maintains another mortgage with Bank of New England for the 2016 purchase of a 45,070 square foot building in Wilmington, Delaware which was developed into a cannabis seed-to-sale facility and is currently leased to the Company’s cannabis-licensed client in that state. The mortgage matures in 2031 with monthly principal and interest payments at a rate of 5.25% per annum through September 2021, and thereafter the rate adjusting every five years to the then prime rate plus 1.5% with a floor of 5.25% per annum. At June 30, 2021 and December 31, 2020, the outstanding principal balance on this mortgage approximated $1.5 million and $1.6 million, respectively, of which approximately $117,000 and $114,000 , respectively, was current. In May 2016, the Company entered into a mortgage agreement with DuQuoin State Bank (“DSB”) for the purchase of two properties which the Company developed into two 3,400 square foot free-standing retail dispensaries in Illinois. On May 5 th 6.75% per annum. At June 30, 2021 and December 31, 2020, the outstanding principal balance on this mortgage approximated $793,000 and $815,000 respectively, of which approximately $32,000 and $31,000 , respectively, was current. In February 2020, the Company entered into a mortgage agreement with South Porte Bank for the purchase and development of a property in Mt. Vernon, IL. Pursuant to amendments to the mortgage agreement, the Company is making interest-only monthly payments at a rate of 5.5% August 31, 2021 Promissory Notes Issued Pursuant to an Exchange Agreement In February 2020, pursuant to an exchange agreement as further described in Note 12 – Mezzanine Equity $4.4 16.5% maturing in August 2021 $4.6 Mezzanine Equity, Promissory Notes Issued by the Company and its MariMed Hemp Inc. Subsidiary In June 2019, the Company and MariMed Hemp Inc., its wholly-owned subsidiary (“MMH”), issued a secured promissory note in the principal amount of $10.0 $1.5 maturity date of January 31, 2020 As part of the $10M Note transaction, the Company issued three-year 375,000 $4.50 $601,000 $523,000 The Company entered into an amendment agreement with the Noteholder in February 2020, whereby the Company and MMH issued an amended and restated promissory note maturing in June 2020 $11,500,000 15% $3,000,000 The Company entered into a second amendment agreement with the Noteholder in June 2020, whereby (i) $352,000 of outstanding principal of the $11.5M Note was converted into 1,900,000 shares of the Company’s common stock (which did not result in a material extinguishment gain or loss as the conversion price approximated the price of the Company’s common stock on the agreement date), and (ii) the Company and MMH issued a second amended and restated promissory note in the principal amount of approximately $8.8 million, comprised of the outstanding principal and unpaid interest balances of the $11.5M Note, plus an extension fee of approximately $ 330,000 15 % per annum and maturing in June 2022 (the “$8.8M Note”). In addition, the Company issued three-year warrants to the Noteholder to purchase up to 750,000 shares of common stock at an exercise price of $0.50 per share. The fair value of these warrants on the issuance date of approximately $66,000 was recorded as a discount to the $8.8M Note, and amortized to interest expense over the life of the $8.8M Note. The Company made a required principal payment of $4,000,000 in July 2020 with a portion of proceeds of the Refinanced Mortgage discussed earlier in this footnote, and additional principal payments of $ 600,000 $4.2 million at December 31, 2020. The Noteholder has the option to convert the $8.8M Note, in whole or in part, into shares of the Company’s common stock at a conversion price of $0.30 per share, subject to certain conversion limitations. This non-detachable conversion feature of the $8.8M Note had no intrinsic value on the agreement date, and therefore no beneficial conversion feature arose. In March 2021, the Noteholder converted $ 1,000,000 10,000 3,365,972 3.2 The Company entered into a third amendment agreement with the Noteholder in April 2021 whereby the Company and MMH issued a third amended and restated promissory note in the principal amount of approximately $3.2 million (the “$3.2M Note”) which bears interest at a rate of 0.12% per annum and matures in April 2023 . The Noteholder has the option to convert, subject to certain conversion limitations, all or a portion of the $3.2M Note into shares of the Company’s common stock at a conversion price of $0.35 per share, such conversion price subject to adjustment in the event of certain transactions by the Company. The third amended agreement resulted in a decrease in the fair value of the embedded conversion feature of the $3.2M Note and therefore no accounting was required for such conversion feature. On or after the one-year anniversary of the $3.2M Note, upon twenty days prior written notice to the Noteholder, the Company can prepay all of the outstanding principal and unpaid interest of the $3.2M Note, along with a prepayment premium equal to 10% of the principal amount being prepaid. The Noteholder shall remain entitled to convert the $3.2M Note during such notice period. On or after the one-year anniversary of the $3.2M Note, the Noteholder has the right to require the redemption in cash of up to $125,000 of principal and unpaid interest thereon per calendar month. The Noteholder converted, during the second quarter of 2021, $ 1,250,000 3,571,428 1.96 Promissory Note Issued by MMH In April 2019, MMH issued a secured promissory note in the principal amount of $1,000,000 (the “$1M Note”) to an unaffiliated party. The principal balance plus a payment of $180,000 , initially due in December 2019, was extended to March 2020 in accordance with the terms of the $1M Note, requiring an additional payment of $30,000 (the “$30,000 Fee”). Prior to the extended due date, the parties agreed that the $1M Note would continue on a month-to-month basis bearing interest at a rate of 15% per annum. In September 2020, the Company paid down $500,000 of principal on the $1M Note, reducing the carrying value of the $1M Note to $ 500,000 Mezzanine Equity, $500,000 was paid down. Promissory Notes Issued for Operating Liquidity In March 2019, the Company raised $6.0 13% $900,000 The $6M Note’s initial maturity date of December 31, 2019 was extended to April 2020 $300,000 The Company and the Holding Party entered into a note extension agreement in April 2020 (the “Initial Extension Agreement”) pursuant to which (i) the $6M Note’s due date was extended to September 2020, and the $6M Note was modified to include unpaid accrued interest of $845,000 10% $900,000 12% $900k $20,100 $460,050 2,525,596 Previous to the $6M Note, the Company raised $3.0 million from the issuance of a secured promissory note to the Holding Party in September 2018, bearing interest at a rate of 10% per annum (the “$3M Note”). The maturity date of the $3M Note, initially in March 2020 , was extended for an additional six months in accordance with its terms, with the interest rate increasing to 12% per annum during the extension period. Pursuant to the Initial Extension Agreement, the maturity date of the $3M Note was extended to December 2020 . As part of the $3M Note transaction, the Company issued three-year warrants to the Holding Party’s designees to purchase 750,000 $1.80 $1,511,000 The Company and the Holding Party entered into a second note extension agreement in October 2020 (the “Second Extension Agreement”) whereby the Company (i) paid $1 million of principal and all outstanding accrued interest of approximately $333,000 on the $6.8M Note; (ii) issued an amended and restated senior secured promissory note in the principal amount of $5,845,000 (the “$5.8M Note”) to replace the $6.8M Note; and (iii) amended and restated the $3M Note (the “New $3M Note”, and together with the $5.8M Note, the “Amended Notes”). The Amended Notes bear interest at a rate of 12% per annum with maturity dates in September 2022 , and can be prepaid in whole or in part at any time. In consideration of the Second Extension Agreement, the Company (i) issued four-year warrants to the Holding Party’s designees to purchase up to 5,000,000 $0.25 $100,000 $573,000 $75,000 $8.3 $1.9 The Company made a required principal payment of $400,000 on the $5.8M Note in February 2021. In March 2021, utilizing a portion of the proceeds from the Hadron transaction discussed in Note 12 – Mezzanine Equity, $450,000 on this note was fully amortized on the payment date. Promissory Notes Issued to Purchase Commercial Vehicles In August 2020, the Company entered into a note agreement with First Citizens’ Federal Credit Union for the purchase of a commercial vehicle. The note bears interest at a rate of 5.74% per annum and matures in July 2026 28,000 30,000 5,000 In June 2021, the Company entered into a note agreement with Ally Financial for the purchase of a second commercial vehicle. The note bears interest at the rate of 10 matures in May 2027 35,000 5,000 Other Promissory Note Issuances In addition to the above transactions, at the start of 2020, the Company was carrying $3,190,000 6.5% 18% $2,147,000 12% 15% $2,100,000 $500,000 $0.32 $700,000 $2,037,000 $200,000 Mezzanine Equity Debt Maturities As of June 30, 2021, the aggregate scheduled maturities of the Company’s total debt outstanding were: SCHEDULE OF AGGREGATE MATURITIES OF DEBT OUTSTANDING 2021 2021 $ 1,151,743 2022 521,091 2023 2,516,622 2024 588,520 2025 629,384 Thereafter 12,504,018 Total 17,911,377 Less discounts (52,050 ) Long-term debt, net $ 17,859,327

DEBENTURES PAYABLE

DEBENTURES PAYABLE	6 Months Ended
	Jun. 30, 2021
Debentures Payable
DEBENTURES PAYABLE	NOTE 11 – DEBENTURES PAYABLE In a series of transactions from the period October 2018 through February 2020, the Company sold an aggregate of $21.0 SCHEDULE OF DEBENTURE TRANSACTION Issue Date Maturity Date Initial Principal Interest Issue Discount Warrant Beneficial Conversion Converted 10/17/18 10/16/20 $ 5,000,000 6.0% 1.0% $ 457,966 $ 1,554,389 $ 5,000,000 11/07/18 11/06/20 5,000,000 6.0% 1.0% 599,867 4,015,515 5,000,000 05/08/19 05/07/21 5,000,000 6.0% 1.0% 783,701 2,537,235 5,000,000 06/28/19 06/27/21 2,500,000 0.0% 7.0% 145,022 847,745 2,500,000 08/20/19 08/19/21 2,500,000 0.0% 7.0% 219,333 850,489 2,500,000 02/21/20 02/20/21 1,000,000 6.5% 6.5% 28,021 379,183 1,000,000 As of June 30, 2021, the holder of the $21M Debentures (the “Holder”) had converted all of the $21M Debentures, along with accrued interest, into the Company’s common stock at conversion prices equal to 80% of a calculated average, as determined in accordance with the terms of the $21M Debentures, of the daily volume-weighted price during the ten consecutive trading days preceding the date of conversion. Specifically, over the life of the $21M Debentures, the Holder converted, in several transactions, an aggregate of $ 21.0 836,000 92,704,035 0.11 3.06 9.7 365,000 77,766,559 0.11 0.34 $1.3 56,000 4,610,645 0.29 All of the aforementioned conversions were effected in accordance with the terms of the convertible debenture agreement, and therefore the Company was not required to record a gain or loss on such conversions. The conversions were limited in any given month to certain agreed-upon amounts based on the conversion price, and the Holder was also limited from beneficially owning more than 4.99% of the Company’s outstanding common stock. In conjunction with the issuance of the $21M Debentures, the Company issued the Holder three 1,354,675 $0.75 $5.50 180,000 $0.75 $2.2 Based on the conversion prices of the $21M Debentures in relation to the market value of the Company’s common stock, the $21M Debentures provided the Holder with a beneficial conversion feature, as the embedded conversion option was in-the-money on the commitment date. The aggregate intrinsic value of the beneficial conversion feature of approximately $10.2 Pursuant to the terms of a registration rights agreement with the Holder, entered into concurrently with the SPA, the Company agreed to provide the Holder with certain registration rights with respect to shares issued pursuant to the terms of the SPA and the $21M Debentures. During the year ended December 31, 2020, amortization of the beneficial conversion features, after adjustment for the aforementioned conversions, approximated $3.2 million; amortization of the warrant discounts approximated $805,000 ; amortization of original issue discounts approximated $321,000 ; and interest expense approximated $224,000 . At December 31, 2020, the aggregate outstanding principal balance of the $21M Debentures was $1.3 million. Also on such date, the unamortized balances of the beneficial conversion features, the warrant discounts, and original issue discounts were approximately $177,000 , $39,000 , and $52,000 , respectively. Accordingly, at December 31, 2020, the carrying value of the $21M Debentures approximated $1,032,000, During the six months ended June 30, 2021, amortization of the beneficial conversion features, after adjustment for the aforementioned conversions, approximated $177,000 ; amortization of the warrant discounts approximated $39,000 ; amortization of original issue discounts approximated $52,000 ; and interest expense approximated $1,000 .

MEZZANINE EQUITY

MEZZANINE EQUITY	6 Months Ended
	Jun. 30, 2021
Mezzanine Equity
MEZZANINE EQUITY	NOTE 12 – MEZZANINE EQUITY Series B Convertible Preferred Stock In February 2020, the Company entered into an exchange agreement with two institutional shareholders (the “TIS Exchange Agreement”) whereby the Company (i) exchanged 4,908,333 Debt In connection with the TIS Exchange Agreement, the Company filed (i) a certificate of designation with respect to the rights and preferences of the Series B convertible preferred stock, and (ii) a certificate of elimination to return all shares of the Series A convertible preferred stock, of which no shares were issued or outstanding at the time of filing, to the status of authorized and unissued shares of undesignated preferred stock. The holders of Series B convertible preferred stock (the “Series B Holders”) are entitled to cast the number of votes equal to the number of shares of common stock into which the shares of Series B convertible preferred stock are convertible, together with the holders of common stock as a single class, on most matters. However, the affirmative vote or consent of the Series B Holders voting separately as a class is required for certain acts taken by the Company, including the amendment or repeal of certain charter provisions, liquidation or winding up of the Company, creation of stock senior to the Series B convertible preferred stock, and/or other acts defined in the certificate of designation. The Series B convertible preferred stock shall, with respect to dividend rights and rights on liquidation, winding up and dissolution, rank senior to the Company’s common stock. The Company shall not declare, pay, or set aside any dividends on shares of any other class or series of capital stock of the Company unless the Series B Holders then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series B convertible preferred stock in an amount calculated pursuant to the certificate of designation. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the Series B Holders then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $3.00 At any time on or prior to the six-year anniversary of the issuance date of the Series B convertible preferred stock, (i) the Series B Holders have the option to convert their shares of Series B convertible preferred stock into common stock at a conversion price of $3.00 $4.00 least twenty consecutive trading days On the day following the six-year anniversary of the issuance of the Series B convertible preferred stock, all outstanding shares of Series B convertible preferred stock shall automatically convert into common stock as follows: If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share. If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option $3.00 The Company shall at all times when the Series B convertible preferred stock is outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Series B convertible preferred stock, such number of its duly authorized shares of common stock as shall from time to time be sufficient to effect the conversion of all outstanding Series B convertible preferred stock. Series C Convertible Preferred Stock In March 2021, the Company entered into a securities purchase agreement with Hadron Healthcare Master Fund (“Hadron”) with respect to a financing facility of up to $46.0 At the closing of the transaction in March 2021, Hadron purchased $23.0 $3.70 four-year 6,216,216 15,540,540 $1.087 $9.5 387,000 In connection with the closing of the transaction, the Company filed a certificate of designation with respect to the rights and preferences of the Series C convertible preferred stock. Such stock is zero coupon, non-voting. and has a liquidation preference equal to its investment amount plus declared but unpaid dividends. Holders of Series C convertible preferred stock are entitled to receive dividends on an as-converted basis. Of the $23.0 million of proceeds received by the Company in March 2021, approximately (i) $7.8 million is designated to fund construction and upgrades of certain of the Company’s owned and managed facilities, of which approximately $ 6.6 million was expended during the six months ended June 30, 2021, and (ii) $15.2 million was used to pay down debt and obligations, comprised of principal and interest on the $4.4M Notes, the $1M Note, the New $3M Note, the $5.8M Note, the Existing Notes, the New 2020 Notes (all referred to in Note 10 – Debt Due To Related Parties Related Party Transactions The balance of the committed facility of up to an additional $23.0 million is intended to fund the Company’s specific targeted acquisitions provided such acquisitions are contracted in 2021 and consummated, including obtaining the necessary regulatory approvals, no later than the end of 2022 Provided that as at least 50% The transaction imposes certain covenants on the Company with respect to the incurrence of new indebtedness, the issuance of additional shares of any designation of preferred stock, and the payment of distributions.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 13 – STOCKHOLDERS’ EQUITY Undesignated Preferred Stock In February 2020, the Company filed a certificate of elimination to return all shares of formerly designated Series A convertible preferred stock to the status of authorized and unissued shares of undesignated preferred stock. Common Stock In February 2020, pursuant to the TIS Exchange Agreement discussed in Note 12 – Mezzanine Equity 4,908,333 14,725,000 3.00 5,000 14,720,000 In the six months ended June 30, 2021 and 2020, the Company granted 6,877 64,478 shares of common stock, respectively, to a current employee. The fair value of the shares of approximately $ 5,000 in 2021 and $ 11,000 34,171 5,000 Common Stock Subscribed But Not Issued In the six months ended June 30, 2021 and 2020, the Company issued 71,691 4,400,000 51,000 699,000 2,500 45,000 Loss On Obligations Settled with Equity During the six months ended June 30, 2021 and 2020, the Company issued 11,413 and 3,236,857 shares of common stock, respectively, associated with previously issued subscriptions on common stock with a value of approximately $ 5,000 and $ 1,168,000 , respectively. As previously disclosed in Note 10 – Debt 6,937,400 shares of common stock in 2021 upon the conversion of approximately $ 2,260,000 of principal and interest on promissory notes, (ii) 1,900,000 shares of common stock in June 2020 to extinguish $ 352,000 of principal on promissory notes, and (iii) 2,525,596 shares common stock in June 2020 upon the conversion of $ 460,050 of principal and interest on promissory notes. As previously disclosed in Note 11 – Debentures Payable 1.4 4,610,645 10.1 77,766,559 As further disclosed in Note 14 – Options, options to purchase 82,885 No As further disclosed in Note 15 – Warrants 698,812 No Common Stock Issuance Obligations At June 30, 2020, the Company was obligated to issue 34,171 shares of common stock valued at approximately $ 5,000 in connection with a stock grant to a current employee. These share were issued in August 2020.

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 14 – STOCK OPTIONS During the six months ended June 30, 2021, the Company granted three five-year options to purchase up to 2,802,000 shares of common stock at exercise prices ranging from $ 0.30 to $ 1.00 per share. The fair value of these options of approximately $ 1,458,000 in the aggregate is being amortized to compensation expense over their respective vesting periods, of which approximately $ 704,000 was amortized during the six months ended June 30, 2021. Additionally, compensation expense in the first half of 2021 for options issued in previous years, and continuing to be amortized over their respective vesting periods, approximated $ 180,000 . During the six months ended June 30, 2020, five-year options to purchase up to 564,500 common shares were issued to employees at an exercise price of $ 0.30 per share. The fair value of these options of approximately $ 67,000 in the aggregate is being amortized to compensation expense over their respective vesting periods, of which approximately $ 25,000 was amortized during the six months ended June 30, 2020. Additionally, compensation expense in the first half of 2020 for options issued in previous years, and continuing to be amortized over their respective vesting periods, approximated $ 549,000 . During the six months ended June 30, 2021, options to purchase 155,000 0.30 0.45 125,000 72,115 During the six months ended June 30, 2021 and 2020, options to purchase 50,000 and 30,000 shares of common stock, respectively, were forfeited or expired, resulting in an aggregate reduction of amortized compensation expense of zero in 2021 and approximately $ 19,000 in 2020. Stock options outstanding and exercisable as of June 30, 2021 were: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Shares Under Option Exercise Price Outstanding Exercisable Remaining Life $ 0.140 160,000 40,000 4.03 $ 0.149 500,000 500,000 4.51 $ 0.169 200,000 200,000 4.37 $ 0.210 70,000 50,000 4.40 $ 0.225 2,000,000 1,062,500 4.36 $ 0.250 20,000 20,000 3.92 $ 0.250 50,000 12,500 4.32 $ 0.250 800,000 400,000 4.37 $ 0.250 80,000 40,000 4.40 $ 0.250 50,000 50,000 3.67 $ 0.300 524,500 262,250 3.75 $ 0.417 900,000 900,000 3.49 $ 0.505 100,000 25,000 4.52 $ 0.505 800,000 100,000 4.53 $ 0.590 15,000 15,000 3.44 $ 0.630 300,000 300,000 0.50 $ 0.740 590,000 338,125 4.83 $ 0.770 200,000 200,000 1.50 $ 0.830 287,000 71,750 4.73 $ 0.830 600,000 4.91 $ 0.850 90,000 25,000 4.96 $ 0.890 10,000 - 4.56 $ 0.892 40,000 10,000 4.56 $ 0.895 25,000 6,250 4.57 $ 0.900 50,000 50,000 1.86 $ 0.910 50,000 50,000 1.31 $ 0.950 50,000 50,000 1.50 $ 0.970 100,000 25,000 4.96 $ 0.983 145,000 - 4.99 $ 0.992 300,000 300,000 3.24 $ 1.000 15,000 15,000 2.96 $ 1.000 125,000 125,000 3.34 $ 1.350 100,000 75,000 2.08 $ 1.950 375,000 375,000 2.00 $ 2.320 100,000 100,000 2.20 $ 2.450 2,000,000 2,000,000 1.48 $ 2.500 100,000 100,000 2.16 $ 2.650 200,000 200,000 2.24 $ 2.850 56,250 56,250 1.45 $ 2.850 100,000 100,000 2.45 $ 3.000 25,000 25,000 2.46 $ 3.725 100,000 100,000 2.44 12,402,750 8,374,625

WARRANTS

WARRANTS	6 Months Ended
	Jun. 30, 2021
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	NOTE 15 – WARRANTS During the six months ended June 30, 2021, the Company issued warrants to purchase up to 1,100,000 shares of common stock at exercise prices of $ 0.82 and $ 0.83 per share, expiring three and four years from issuance. The fair value of these warrants on their issuance dates approximated $ 710,000 in the aggregate which was charged to compensation expense. Also during this period, the Company issued warrants to Hadron to purchase up to 15,540,540 shares of common stock at an exercise price of $ 1.087 per share, expiring four years from issuance, as part of the Hadron transaction previously discussed in Note 12 – Mezzanine Equity 9.5 million, and this amount was allocated to the warrant from the $ 23.0 million proceeds from the Hadron transaction and recorded in additional paid in capital. During the six months ended June 30, 2020, in conjunction with the $21M Debentures discussed in Note 11 – Debentures Payable three -year warrants to purchase up to 180,000 shares of common stock at an exercise price of $ 0.75 per share. Also during this period, in conjunction with the $8.8M Note discussed in Note 10 – Debt 750,000 shares of common stock at an exercise price of $ 0.50 per share The fair value of these warrants on their issuances dates approximated $ 94,000 in the aggregate , of which approximately $ 20,000 was amortized to interest expense in the period and the remainder to be amortized over the terms of the respective debt instruments. During the six months ended June 30, 2021, warrants to purchase 956,250 shares of common stock were exercised at exercise prices ranging from $ 0.11 0.55 per share. No warrants were exercised during the same period in 2020. During the six months ended June 30, 2021, warrants to purchase 3,426,500 shares of common stock with exercise prices of $ 0.90 and $ 2.25 per share were forfeited. No warrants were forfeited during the same period in 2020. At June 30, 2021 and 2020, warrants to purchase up to 29,174,958 and 12,710,107 shares of common stock, respectively, were outstanding with exercise prices ranging from $ 0.11 to $ 5.50 per share across both periods.

REVENUES

REVENUES	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
REVENUES	NOTE 16 – REVENUES For the six months ended June 30, 2021 and 2020, the Company’s revenues were comprised of the following major categories: SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES 2021 2020 Product sales - retail $ 35,776,191 $ 9,942,804 Product sales - wholesale 13,902,969 1,277,076 Real estate rentals 3,670,462 3,492,042 Management fees 1,877,407 748,696 Supply procurement 918,018 818,900 Licensing fees 1,067,173 796,847 Total revenues $ 57,212,220 $ 17,076,325 For the six months ended June 30, 2021 and 2020, revenues from two clients represented 12 % and 30 %, respectively, of total revenues.

BAD DEBTS

BAD DEBTS	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
BAD DEBTS	NOTE 17 – BAD DEBTS The Company maintains two types of reserves to address uncertain collections of amounts due—an allowance against trade accounts receivable (the “AR Allowance”), and a reserve against cash advanced by the Company to its cannabis-licensed clients for working capital purposes (the WC Reserve”). During the six months ended June 30, 2021, the Company increased the AR Allowance by $ 1,400,000 , and the WC Reserve by approximately $ 419,000 . The aggregate of these two amounts of approximately $ 1,819,000 was charged to Bad Debts 450,000 Bad Debts

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 18 – RELATED PARTY TRANSACTIONS In April 2020, the Company issued options to purchase up to 50,000 0.30 6,000 In 2020, options to purchase an aggregate of 550,000 shares of common stock were exercised by the Company’s CEO, CFO, and an independent board member at exercise prices of $ 0.13 and $ 0.14 per share. No options were exercised by related parties in 2021. The Company’s corporate offices are leased from an entity in which the Company’s CFO has an investment interest. This lease expires in October 2028 and contains a five-year extension option. In each of the six-month periods ended June 30, 2021 and 2020, expenses incurred under this lease approximated $ 78,000 . The Company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the Company’s COO. The aggregate purchases from this entity in the six months ended June 30, 2021 and 2020 approximated $ 2,015,000 and $ 1,141,000 , respectively. The Company pays royalties on the revenue generated from its Betty’s Eddies® product line to an entity owned by the Company’s COO and its SVP of Sales under a royalty agreement. This agreement was amended effective January 1, 2021 whereby, among other modifications, the royalty percentage changed from 2.5 % on all sales of Betty’s Eddies® products to (i) 3.0% and 10.0% of wholesale sales of existing products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively, and (ii) 0.5% and 1.0% of wholesale sales of future developed products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively. The aggregate royalties due to this entity in the six months ended June 30, 2021 and 2020 approximated $ 162,000 and $ 148,000 , respectively. In the six months ended June 30, 2021 and 2020, one of the Company’s majority owned subsidiaries paid aggregate distributions of approximately $ 21,000 and $ 19,000 , respectively, to the Company’s CEO and CFO, who own minority equity interests in such subsidiary. In the six months ended June 30, 2021, the Company purchased fixed assets and consulting services of approximately $ 573,000 in the aggregate from two entities owned by two of the Company’s general managers. No payments were made to these two entities in the same period in 2020. In the six months ended June 30, 2021 and 2020, the Company purchased fixed assets of approximately $ 466,000 145,000 from an entity owned by an employee. The balance of Due To Related Parties 1.2 460,000 653,000 45,000 The Company’s mortgages with Bank of New England, DuQuoin State Bank, and South Porte Bank are personally guaranteed by the Company’s CEO and CFO.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 19 – COMMITMENTS AND CONTINGENCIES Lease Commitments The Company is the lessee under six four finance leases The details of the Company’s operating lease agreements are as follows: ● Delaware – 4,000 five-year lease that expires in December 2021 with a five-year option to extend ● Delaware – a 100,000 The lease term is 10 ● Delaware –a 12,000 expires in January 2026 ● Nevada – 10,000 expiring in 2024 ● Massachusetts – 10,000 10 expiring in 2028 option to extend the term for an additional five-year period ● Maryland – a 2,700 expires in July 2022 The Company leases machinery and office equipment under finance leases that expire in February 2022 through June 2024 The components of lease expense for the three months ended June 30, 2021 were as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE Operating lease cost $ 543,593 Finance lease cost: Amortization of right-of-use assets $ 16,342 Interest on lease liabilities 2,855 Total finance lease cost $ 19,197 The weighted average remaining lease term for operating leases is 7.8 years, and for the finance leases is 2.4 years. The weighted average discount rate used to determine the right-of-use assets and lease liabilities was between 7.5 % to 12 % for all leases. Future minimum lease payments as of June 30, 2021 under all non-cancelable leases having an initial or remaining term of more than one year were: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON-CANCELABLE OPERATING LEASES Operating Finance 2021 $ 564,469 $ 19,206 2022 1,071,079 27,123 2023 1,035,017 23,201 2024 963,589 3,229 2025 936,947 - Thereafter 3,468,041 - Total lease payments 8,039,142 $ 72,759 Less: imputed interest (2,058,393 ) (6,208 ) $ 5,980,749 $ 66,551 Terminated Employment Agreement An employment agreement which commenced in 2012 with Thomas Kidrin, the former CEO of the Company, which provided Mr. Kidrin with salary, car allowances, stock options, life insurance, and other employee benefits, was terminated by the Company in 2017 1,043,000 In July 2019, Mr. Kidrin, also a former director of the Company, filed a complaint in the Massachusetts Superior Court, which alleges the Company failed to pay all wages owed to him and breached the employment agreement, and requests multiple damages, attorney fees, costs, and interest. The Company has moved to dismiss certain counts of the complaint and has asserted counterclaims against Mr. Kidrin alleging breach of contract, breach of fiduciary duty, money had and received, and unjust enrichment. The Company believes that the allegations in the complaint are without merit and intends to vigorously defend this matter and prosecute its counterclaims. While the Company’s motion to dismiss was pending, the parties reached a settlement in principle and the court has issued a nisi Maryland Acquisition As previously disclosed in Note 3 – Acquisitions In November 2019, Kind commenced an action by filing a complaint against the Company in the Circuit Court for Washington County, MD captioned Kind Therapeutics USA, Inc. vs. MariMed, Inc., et al. (Case No. C-21-CV-19-000670) (the “Complaint”). The Complaint, as amended, alleges breach of contract, breach of fiduciary duty, unjust enrichment, intentional misrepresentation, rescission, civil conspiracy, and seeking an accounting and declaratory judgment and damages in excess of $ 75,000 At the time the Complaint and Counterclaims were filed, both parties, MariMed (including MariMed Holdings MD, LLC and MariMed Advisors Inc.) and Kind, brought motions for a temporary restraining order and a preliminary injunction. By Opinion and Order entered on November 21, 2019, the Court denied both parties motions for a temporary restraining order. In its opinion, the Court specifically noted that, contrary to Kind’s allegations, the MSA and the Lease “appear to be independent, valid and enforceable contracts.” A hearing on the parties’ cross-motions for preliminary injunction was held in September 2020 and November 2020. Also in November 2020, the Court granted the Company’s motion for summary judgment as to the Lease, determining that the Lease is valid and enforceable. Based on this ruling, the Company is seeking judgment at trial in the amount of approximately $ 5.4 In December 2020, the Court entered a Preliminary Injunction Order, accompanied by a Memorandum Opinion, denying Kind’s motion for a preliminary injunction (which Kind had withdrawn at the conclusion of the hearing) and granting the Company’s request for preliminary injunction. The Court determined that the Company is likely to succeed with respect to the validity and enforceability of the MSA and the LMA, that the Company would suffer substantial and irreparable harm without the preliminary injunction, and that the balance of convenience and public interest both warranted the issuance of a preliminary injunction in the Company’s favor. The Court ordered, inter alia, that the MSA and LMA are in effect pending judgment after trial on the merits, and that Kind and its members, and their attorneys, agents, employees, and representatives, are prohibited from (a) interfering with the Company’s duties and responsibilities under the MSA and (b) withdrawing funds, making any distribution, paying any loans, returning any capital, or making any payment towards a debt from any Kind bank or other financial account(s) without written consent of the Company or Order of the Court, thereby preserving the Company’s management of Kind’s operations and finances at least through the jury trial currently scheduled to begin on March 28, 2022. Further, the Court ordered Kind to pay management and licensing fees to the Company beginning January 1, 2021. Kind has noted an appeal of the Order to the Maryland Court of Special Appeals, which is pending; however, the preliminary injunction order remains in effect. In addition to the favorable rulings on the Lease, MSA, and LMA, the Company believes that its claims with respect to the 70%/30% partnership/joint venture agreement are meritorious. Further, the Company believes that Kind’s claims against the Company are without merit. On March 18, 2021, the Court issued an opinion and order on Kind’s motion for summary judgment finding that the MOU was not enforceable by the Company against Kind as a final binding agreement. The Company is evaluating an appeal of this ruling which under Maryland rules can only be pursued upon final judgment. In March 2021, the Kind parties filed motions to modify the preliminary injunction order or, alternatively, for direction from the Court based on Kind’s claim to have terminated the MSA. The Company has opposed both motions and has filed a petition for civil contempt against the Kind parties for interfering with the Company’s management of Kind. The motions and petition are pending, and the preliminary injunction remains in effect. The Company intends to aggressively prosecute and defend the action. Trial has been scheduled from March 28, 2022 to April 11, 2022. DiPietro Lawsuit In August 2020, Jennifer DiPietro, directly and derivatively on behalf of Mari Holdings MD LLC (“Mari-MD”) and Mia Development LLC (“Mia”), commenced a suit against the Company’s CEO, CFO, and wholly-owned subsidiary MariMed Advisors Inc. (“MMA”), in Suffolk Superior Court, Massachusetts. In this action, DiPietro, a party to prior ongoing litigation in Maryland involving the Company and Kind as discussed above, brings claims for breach of fiduciary duty, breach of contract, fraud in the inducement, aiding and abetting the alleged breach of fiduciary duty, and also seeks access to books and records and an accounting related to her investments in Mari-MD and Mia. DiPietro seeks unspecified money damages and rescission of her interest in Mari-MD, but not of her investment in Mia, which has provided substantial returns to her as a member. The Company has answered the complaint and MMA filed counterclaims against DiPietro on its own behalf and derivatively on behalf of Mari-MD for breach of her fiduciary duties to each of those entities, and for tortious interference with Mari-MD’s lease and MMA’s management services agreement with Kind. The Company believes that the allegations of the complaint are without merit and intends to defend the case vigorously. The Company’s counterclaim seeks monetary damages from DiPietro, including the Company’s legal fees in the Kind action. Bankruptcy Claim During 2019, the Company’s MMH subsidiary sold and delivered hemp seed inventory to GenCanna Global Inc., a Kentucky-based cultivator, producer, and distributor of hemp (“GenCanna”). At the time of sale, the Company owned a 33.5 29.0 In February 2020, GenCanna USA, GenCanna’s wholly-owned operating subsidiary, under pressure from certain of its creditors including MGG Investment Group LP, GenCanna’s senior lender (“MGG”), agreed to convert a previously-filed involuntary bankruptcy proceeding with the U.S. Bankruptcy Court in the Eastern District of Kentucky (the “Bankruptcy Court”) into a voluntary Chapter 11 proceeding. In addition, GenCanna and GenCanna USA’s subsidiary, Hemp Kentucky LLC (collectively with GenCanna and GenCanna USA, the “GenCanna Debtors”), filed voluntary petitions under Chapter 11 in the Bankruptcy Court. In May 2020, after an abbreviated solicitation/bid/sale process, the Bankruptcy Court, over numerous objections by creditors and shareholders of the GenCanna Debtors which included the Company, entered an order authorizing the sale of all or substantially all of the assets of the GenCanna Debtors to MGG. After the consummation of the sale of all or substantially all of their assets and business, the GenCanna Debtors n/k/a OGGUSA, Inc. and OGG, Inc. (the “OGGUSA Debtors”) filed their liquidating plan of reorganization (the “Liquidating Plan”) to collect various prepetition payments and commercial claims against third parties, liquidate the remaining assets of the ODDUSA Debtors, and make payments to creditors. The Company and the unsecured creditors committee filed objections to such Liquidating Plan, including opposition to the release of litigation against the OGGUSA Debtors’ senior lender, MGG, for lender liability, equitable subordination, and return of preference. As a part of such plan confirmation process, the OGGUSA Debtors filed various objections to proofs of claims filed by various creditors, including the proof of claim in the amount of approximately $ 33.6 31.0 Since the approval of the Liquidating Plan, the OGGUSA Debtors have been in the process of liquidating the remaining assets, negotiating and prosecuting objections to other creditors’ claims, and pursuing the collection of accounts receivable and Chapter 5 bankruptcy avoidance claims. As of the date of this filing, there is insufficient information as to what portion, if any, of the Company’s allowed claim will be paid upon the completion of the liquidation of the remaining assets of the OGGUSA Debtors.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20 – SUBSEQUENT EVENTS Metropolis Property Purchase In July 2021, the Company purchased the land and building in which it operates its cannabis dispensary in Metropolis, IL. The purchase price consisted of 750,000 shares of the Company’s common stock, which was valued at $ 705,000 on the date of the transaction, and payoff of the seller’s remaining mortgage of approximately $ 1.6 million. In connection with this purchase, the Company entered into another mortgage agreement with DuQuoin State Bank in the amount of $ 2.7 million that matures in July 2041 and initially bears interest at a rate of 6.25% per annum, and adjusted each year based on a certain interest rate index plus a margin. As part of this transaction, the seller was provided with a 30% ownership interest in Mari Holdings Metropolis LLC (“Metro”), the Company’s subsidiary that will own the property and related mortgage obligation, reducing the Company’s ownership interest in Metro to 70%. Employment Agreements Effective July 1, 2021, the Company entered into employment agreements with its CEO, CFO, and COO, expiring in June 2024 , that provide an annual base salary of $ 350,000 , $325,000 , and $ 300,000 , respectively, and the ability to receive annual bonuses of up to 75% of the executive’s annual base salary for each year during the term, based on reaching certain performance goals established by the Company. The agreements also provide the CEO, CFO, and COO with a grant of non-qualified stock options to purchase up to (i) 5,000,000 , 5,000,000 , and 1,250,000 shares, respectively, of the Company’s common stock, exercisable at the fair market value of the Company’s common stock on the date of the agreements, which fully vest over one year and expire in July 2026 , (ii) 5,000,000 , 5,000,000 , and 1,250,000 shares, respectively, of the Company’s common stock, exercisable at the fair market value of the Company’s common stock on the date that the Company’s stockholders approve an amendment to the Company’s Amended and Restated 2018 Stock Award and Incentive Plan, which fully vest over one year and expire five years from grant date; and (iii) additional grants on each anniversary of the effective date of the agreements in the sole discretion of the Company’s Compensation Committee. The agreements include covenants not to compete, non-solicitation provisions, and termination obligations, among other terms and conditions. Promissory Note Conversions In August 2021, the Noteholder of the $3.2M Note converted approximately $ 387,000 1,104,725 Equity Transactions In July 2021, the Company granted (i) five-year options to purchase up to an aggregate of 11,250,000 shares of the Company’s common stock to the Company’s CEO, CFO, and COO pursuant to the aforementioned employment agreements at an exercise price of $0.88 per share (ii) five -year options to purchase up to 100,000 shares of common stock to each of the Company’s three independent board members at an exercise price of $ 0.88 per share, (ii) five-year options to purchase up to an aggregate of 900,000 shares of common stock to employees at exercise prices of $ 0.84 and $ 0.90 per share, and (ii) an aggregate of 145,217 shares of restricted common stock to employees that fully vest in two and three years. Also during this period, (i) options to purchase 85,000 were exercised at exercise prices of $ 0.21 0.30 per share, (ii) 79,815 750,000 300,000 .

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In accordance with GAAP, interim financial statements are not required to contain all of the disclosures normally required in annual financial statements. In addition, the results of operations of interim periods may not necessarily be indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s most recent audited annual financial statements and accompanying notes for the year ended December 31, 2020. Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries at June 30, 2021: SCHEDULE OF MAJORITY OWNED SUBSIDIARIES Subsidiary: Percentage MariMed Advisors Inc. 100.0% Mia Development LLC 89.5% Mari Holdings IL LLC 100.0% Mari Holdings MD LLC 97.4% Mari Holdings NV LLC 100.0% Mari Holdings Metropolis LLC 100.0% Mari Holdings Mt. Vernon LLC 100.0% Hartwell Realty Holdings LLC 100.0% iRollie LLC 100.0% ARL Healthcare Inc. 100.0% KPG of Anna LLC 100.0% KPG of Harrisburg LLC 100.0% MariMed Hemp Inc. 100.0% MediTaurus LLC 70.0% Intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values. The Company’s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the normal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard.
Accounts Receivable	Accounts Receivable Accounts receivable consist of trade receivables and are carried at their estimated collectible amounts. The Company provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding balances with consideration towards such client’s historical collection experience, as well as prevailing economic and market conditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $41.4 million and $40.0 million at June 30, 2021 and December 31, 2020, respectively. Please refer to Note 17 – Bad Debts
Inventory	Inventory Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard criteria. The Company reviews physical inventory for obsolescence and/or excess and will record a write-down if necessary.
Investments	Investments Investments are comprised of equity holdings in private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments are deemed to have occurred.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract with Customers, ● Identify the contract(s) with a customer; ● Identify the performance obligations in the contract(s); ● Determine the transaction price; ● Allocate the transaction price to the performance obligations in the contract(s); and ● Recognize revenue as the performance obligation is satisfied. Additionally, when another party is involved in providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other party—is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging for goods or services to be provided by the other party. The Company is typically considered the principal if it controls the specified good or service before such good or service is transferred to its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations and risks, (ii) possesses certain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance obligations it does not satisfy. The Company’s main sources of revenue are comprised of the following: ● Product Sales – direct sales of cannabis and cannabis-infused products by the Company’s retail dispensaries and wholesale operations in Massachusetts and Illinois, and sales of hemp and hemp-infused products. An increase in product sales is expected from the Company’s planned cannabis-licensee acquisitions in Maryland, Nevada, and Delaware (upon this state’s amendment to permit for-profit ownership of cannabis entities). This revenue is recognized when products are delivered or at retail points-of-sale. ● Real Estate – rental income and additional rental fees generated from leasing of the Company’s state-of-the-art, regulatory-compliant cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed specified amounts. ● Management – fees for providing the Company’s cannabis clients with comprehensive oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue and are recognized after services have been performed. ● Supply Procurement – the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies, and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser. ● Licensing – royalties from the licensed distribution of the Company’s branded products including Kalm Fusion® and Betty’s Eddies®, and from sublicensing of contracted brands including Healer and Tikun Olam, to regulated dispensaries throughout the United States and Puerto Rico. The recognition of this revenue occurs when the products are delivered.
Research and Development Costs	Research and Development Costs Research and development costs are charged to operations as incurred.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred. The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, forty years the remaining duration of the related lease seven ten ten years The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment loss is measured by the excess of the asset’s carrying amount over its estimated fair value. Impairment analyses are based on management’s current plans, asset holding periods, and currently available market information. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements. For the six months ended June 30, 2021 and 2020, based on the results of management’s impairment analyses, there were no impairment losses.
Leases	Leases The consolidated financial statements reflect the Company’s adoption of ASC 842, Leases ASC 842 is intended to improve financial reporting of leasing transactions. The most prominent change from previous accounting guidance is the requirement to recognize right-of-use assets and lease liabilities on the consolidated balance sheet representing the rights and obligations created by operating leases that extend more than twelve months in which the Company is the lessee. The Company elected the package of practical expedients permitted under ASC 842. Accordingly, the Company accounted for its existing operating leases that commenced before the effective date as operating leases under the new guidance without reassessing (i) whether the contracts contain a lease, (ii) the classification of the leases (iii) the accounting for indirect costs as defined in ASC 842. The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Non-lease components within lease agreements are accounted for separately. Right-of-use assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows the provisions of ASC 820, Fair Value Measurement Financial Instruments, Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable, approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by the Company during the six months ended June 30, 2021 and 2020: SCHEDULE OF ASSUMPTIONS USED Six Months Ended June 30, 2021 2020 Life of instrument 3.0 5.0 3.0 Volatility factors 1.230 1.266 1.059 1.180 Risk-free interest rates 0.36 0.90% 0.33 1.33% Dividend yield 0 0% The expected life of an instrument is calculated using the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based Payment The Company amortizes the fair value of option and warrant issuances on a straight-line basis over the requisite service period of each instrument.
Extinguishment of Liabilities	Extinguishment of Liabilities The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation,
Income Taxes	Income Taxes The Company uses the asset and liability method to account for income taxes in accordance with ASC 740, Income Taxes ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no
Related Party Transactions	Related Party Transactions The Company follows ASC 850, Related Party Disclosures In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.
Comprehensive Income	Comprehensive Income The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income
Earnings Per Share	Earnings Per Share Earnings per common share is computed pursuant to ASC 260, Earnings Per Share As of June 30, 2021 and 2020, there were potentially dilutive securities convertible into shares of common stock comprised of (i) stock options – convertible into 12,402,750 6,805,750 29,174,958 12,710,107 4,908,333 31,081,080 zero zero 46,410,593 5,605,260 29,421,133 For the three and six months ended June 30, 2021, the aforementioned potentially dilutive securities increased the number of weighted average common shares outstanding on a diluted basis by 45,990,319 shares and 43,583,063 shares, respectively, in accordance with ASC 260, and are included in the calculation of diluted net income per share for such periods. For the three and six months ended June 30, 2020, the potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculations, resulting in identical basic and fully diluted net income per share for that period.
Commitments and Contingencies	Commitments and Contingencies The Company follows ASC 450, Contingencies If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.
Beneficial Conversion Features on Convertible Debt	Beneficial Conversion Features on Convertible Debt Convertible instruments that are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging A beneficial conversion feature is a nondetachable conversion feature that is “in-the-money” at the commitment date. The in-the-money portion, also known as the intrinsic value, is recorded in equity, with an offsetting discount to the carrying amount of convertible debt to which it is attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization upon full or partial conversions of the debt.
Risk and Uncertainties	Risk and Uncertainties The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.
Noncontrolling Interests	Noncontrolling Interests Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.
Off Balance Sheet Arrangements	Off Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SCHEDULE OF MAJORITY OWNED SUBSIDIARIES	The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries at June 30, 2021: SCHEDULE OF MAJORITY OWNED SUBSIDIARIES Subsidiary: Percentage MariMed Advisors Inc. 100.0% Mia Development LLC 89.5% Mari Holdings IL LLC 100.0% Mari Holdings MD LLC 97.4% Mari Holdings NV LLC 100.0% Mari Holdings Metropolis LLC 100.0% Mari Holdings Mt. Vernon LLC 100.0% Hartwell Realty Holdings LLC 100.0% iRollie LLC 100.0% ARL Healthcare Inc. 100.0% KPG of Anna LLC 100.0% KPG of Harrisburg LLC 100.0% MariMed Hemp Inc. 100.0% MediTaurus LLC 70.0%
SCHEDULE OF ASSUMPTIONS USED	SCHEDULE OF ASSUMPTIONS USED Six Months Ended June 30, 2021 2020 Life of instrument 3.0 5.0 3.0 Volatility factors 1.230 1.266 1.059 1.180 Risk-free interest rates 0.36 0.90% 0.33 1.33% Dividend yield 0 0%

INVESTMENTS (Tables)

INVESTMENTS (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of Investments [Abstract]
SCHEDULE OF INVESTMENTS	At June 30, 2021 and December 31, 2020, the Company’s investments were comprised of the following: SCHEDULE OF INVESTMENTS June 30, December 31, Current investments: Flowr Corp. (formerly Terrace Inc.) $ 941,910 $ 1,357,193 Non-current investments: MembersRSVP LLC 1,165,788 1,165,788 Total investments $ 2,107,698 $ 2,522,981

DEFERRED RENTS RECEIVABLE (Tabl

DEFERRED RENTS RECEIVABLE (Tables)	6 Months Ended
	Jun. 30, 2021
Deferred Rents Receivable
SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON-CANCELABLE LEASES AND SUBLEASES	Future minimum rental receipts for non-cancelable leases and subleases as of June 30, 2021 were: SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON-CANCELABLE LEASES AND SUBLEASES 2021 2021 $ 2,411,711 2022 4,740,130 2023 4,446,410 2024 4,506,585 2025 4,574,023 Thereafter 39,591,553 Total $ 60,270,412

NOTES RECEIVABLE (Tables)

NOTES RECEIVABLE (Tables)	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
SCHEDULE OF NOTES RECEIVABLE	At June 30, 2021 and December 31, 2020, notes receivable, including accrued interest, consisted of the following: SCHEDULE OF NOTES RECEIVABLE June 30, December 31, First State Compassion Center $ 437,014 $ 468,985 Healer LLC 879,642 899,226 High Fidelity Inc. 254,919 254,919 Total notes receivable 1,571,575 1,623,130 Notes receivable, current portion 377,127 658,122 Notes receivable, less current portion $ 1,194,448 $ 965,008

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	At June 30, 2021 and December 31, 2020, inventory was comprised of the following: SCHEDULE OF INVENTORY June 30, December 31, Plants $ 3,570,394 $ 3,352,425 Ingredients and other raw materials 245,353 176,338 Work-in-process 326,095 468,377 Finished goods 5,086,256 2,833,431 Total inventory $ 9,228,098 $ 6,830,571

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	At June 30, 2021 and December 31, 2020, property and equipment consisted of the following: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, December 31, Land $ 3,988,810 $ 3,988,810 Buildings and building improvements 31,187,512 29,309,856 Tenant improvements 9,044,543 8,844,974 Furniture and fixtures 796,742 619,880 Machinery and equipment 6,058,423 4,620,924 Construction in progress 7,424,950 3,140,807 58,500,981 50,525,251 Less: accumulated depreciation (5,834,949 ) (4,888,722 ) Property and equipment, net $ 52,666,031 $ 45,636,529

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
SCHEDULE OF MORTGAGES PAYABLE	At June 30, 2021 and December 31, 2020, mortgage balances, including accrued interest, were comprised of the following: SCHEDULE OF MORTGAGES PAYABLE June 30, December 31, Bank of New England – Massachusetts properties $ 12,665,790 $ 12,834,090 Bank of New England – Delaware property 1,519,716 1,575,658 DuQuoin State Bank – Illinois properties 793,733 814,749 South Porte Bank – Illinois property 855,564 906,653 Total mortgages payable 15,834,803 16,131,150 Mortgages payable, current portion (1,350,548 ) (1,387,014 ) Mortgages payable, less current portion $ 14,484,255 $ 14,744,136
SCHEDULE OF AGGREGATE MATURITIES OF DEBT OUTSTANDING	As of June 30, 2021, the aggregate scheduled maturities of the Company’s total debt outstanding were: SCHEDULE OF AGGREGATE MATURITIES OF DEBT OUTSTANDING 2021 2021 $ 1,151,743 2022 521,091 2023 2,516,622 2024 588,520 2025 629,384 Thereafter 12,504,018 Total 17,911,377 Less discounts (52,050 ) Long-term debt, net $ 17,859,327

DEBENTURES PAYABLE (Tables)

DEBENTURES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2021
Debentures Payable
SCHEDULE OF DEBENTURE TRANSACTION	SCHEDULE OF DEBENTURE TRANSACTION Issue Date Maturity Date Initial Principal Interest Issue Discount Warrant Beneficial Conversion Converted 10/17/18 10/16/20 $ 5,000,000 6.0% 1.0% $ 457,966 $ 1,554,389 $ 5,000,000 11/07/18 11/06/20 5,000,000 6.0% 1.0% 599,867 4,015,515 5,000,000 05/08/19 05/07/21 5,000,000 6.0% 1.0% 783,701 2,537,235 5,000,000 06/28/19 06/27/21 2,500,000 0.0% 7.0% 145,022 847,745 2,500,000 08/20/19 08/19/21 2,500,000 0.0% 7.0% 219,333 850,489 2,500,000 02/21/20 02/20/21 1,000,000 6.5% 6.5% 28,021 379,183 1,000,000

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE	Stock options outstanding and exercisable as of June 30, 2021 were: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Shares Under Option Exercise Price Outstanding Exercisable Remaining Life $ 0.140 160,000 40,000 4.03 $ 0.149 500,000 500,000 4.51 $ 0.169 200,000 200,000 4.37 $ 0.210 70,000 50,000 4.40 $ 0.225 2,000,000 1,062,500 4.36 $ 0.250 20,000 20,000 3.92 $ 0.250 50,000 12,500 4.32 $ 0.250 800,000 400,000 4.37 $ 0.250 80,000 40,000 4.40 $ 0.250 50,000 50,000 3.67 $ 0.300 524,500 262,250 3.75 $ 0.417 900,000 900,000 3.49 $ 0.505 100,000 25,000 4.52 $ 0.505 800,000 100,000 4.53 $ 0.590 15,000 15,000 3.44 $ 0.630 300,000 300,000 0.50 $ 0.740 590,000 338,125 4.83 $ 0.770 200,000 200,000 1.50 $ 0.830 287,000 71,750 4.73 $ 0.830 600,000 4.91 $ 0.850 90,000 25,000 4.96 $ 0.890 10,000 - 4.56 $ 0.892 40,000 10,000 4.56 $ 0.895 25,000 6,250 4.57 $ 0.900 50,000 50,000 1.86 $ 0.910 50,000 50,000 1.31 $ 0.950 50,000 50,000 1.50 $ 0.970 100,000 25,000 4.96 $ 0.983 145,000 - 4.99 $ 0.992 300,000 300,000 3.24 $ 1.000 15,000 15,000 2.96 $ 1.000 125,000 125,000 3.34 $ 1.350 100,000 75,000 2.08 $ 1.950 375,000 375,000 2.00 $ 2.320 100,000 100,000 2.20 $ 2.450 2,000,000 2,000,000 1.48 $ 2.500 100,000 100,000 2.16 $ 2.650 200,000 200,000 2.24 $ 2.850 56,250 56,250 1.45 $ 2.850 100,000 100,000 2.45 $ 3.000 25,000 25,000 2.46 $ 3.725 100,000 100,000 2.44 12,402,750 8,374,625

REVENUES (Tables)

REVENUES (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES	For the six months ended June 30, 2021 and 2020, the Company’s revenues were comprised of the following major categories: SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES 2021 2020 Product sales - retail $ 35,776,191 $ 9,942,804 Product sales - wholesale 13,902,969 1,277,076 Real estate rentals 3,670,462 3,492,042 Management fees 1,877,407 748,696 Supply procurement 918,018 818,900 Licensing fees 1,067,173 796,847 Total revenues $ 57,212,220 $ 17,076,325

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF LEASE EXPENSE	The components of lease expense for the three months ended June 30, 2021 were as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE Operating lease cost $ 543,593 Finance lease cost: Amortization of right-of-use assets $ 16,342 Interest on lease liabilities 2,855 Total finance lease cost $ 19,197
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON-CANCELABLE OPERATING LEASES	Future minimum lease payments as of June 30, 2021 under all non-cancelable leases having an initial or remaining term of more than one year were: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON-CANCELABLE OPERATING LEASES Operating Finance 2021 $ 564,469 $ 19,206 2022 1,071,079 27,123 2023 1,035,017 23,201 2024 963,589 3,229 2025 936,947 - Thereafter 3,468,041 - Total lease payments 8,039,142 $ 72,759 Less: imputed interest (2,058,393 ) (6,208 ) $ 5,980,749 $ 66,551

SCHEDULE OF MAJORITY OWNED SUBS

SCHEDULE OF MAJORITY OWNED SUBSIDIARIES (Details)	Jun. 30, 2021
MariMed Advisors Inc. [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
Mia Development LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	89.50%
Mari Holdings IL LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
Mari Holdings MD LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	97.40%
Mari Holdings NV LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
Mari Holdings Metropolis LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
Mari Holdings Mt. Vernon LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
Hartwell Realty Holdings LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
iRollie LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
ARL Healthcare Inc. [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
KPG of Anna LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
KPG of Harrisburg LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
MariMed Hemp Inc. [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	100.00%
Meditaurus LLC [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Percentage owned	70.00%

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)	Jun. 30, 2021ft²
Accounting Policies [Abstract]
Area of land	300,000

SCHEDULE OF ASSUMPTIONS USED (D

SCHEDULE OF ASSUMPTIONS USED (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Debt instrument, measurement input	0	0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Fair value assumptions, measurement input, volatility factor	$ 1.230	$ 1.059
Fair value assumptions, measurement input, risk free interest rates	0.36%	0.33%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Fair value assumptions, measurement input, volatility factor	$ 1.266	$ 1.180
Fair value assumptions, measurement input, risk free interest rates	0.90%	1.33%
Measurement Input, Expected Term [Member]
Property, Plant and Equipment [Line Items]
Fair value assumptions, measurement input, term		3 years
Measurement Input, Expected Term [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Fair value assumptions, measurement input, term	3 years
Measurement Input, Expected Term [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Fair value assumptions, measurement input, term	5 years

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Unrecognized tax benefits	$ 0	$ 0	$ 0
Share-based Payment Arrangement, Option [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities		12,402,750	6,805,750
Warrant [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities		29,174,958	12,710,107
Series B Preferred Stocks [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities		4,908,333	4,908,333
Series C Preferred Stocks [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities		31,081,080	0
Convertible Debt Securities [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities		0	46,410,593
Promissory Notes [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities		5,605,260	29,421,133
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities	45,990,319	43,583,063
Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life, description		forty years
Tenant Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life, description		the remaining duration of the related lease
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life, description		seven
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life, description		ten
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life, description		ten years
Accounts Receivable [Member]
Property, Plant and Equipment [Line Items]
Bad Debt Reserve, Tax Purpose of Qualified Lender	$ 41,400,000	$ 41,400,000		$ 40,000,000

ACQUISITIONS (Details Narrative

ACQUISITIONS (Details Narrative) $ in Millions	Dec. 31, 2019USD ($)	Aug. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)ft²shares	Jun. 30, 2021ft²	Oct. 31, 2019ft²	Dec. 21, 2018	Dec. 31, 2016
Business Acquisition [Line Items]
Area of land | ft²				300,000
Members Kind Therapeutics USA Inc [Member]
Business Acquisition [Line Items]
Equity onwership percentage							30.00%
The Harvest Foundation LLC [Member]
Business Acquisition [Line Items]
Percentage of interests acquired in business acquisition		100.00%
The Harvest Foundation LLC [Member] | Two Owners [Member]
Business Acquisition [Line Items]
Sale of stock, shares | shares		1,000,000
Sale of stock, value | $		$ 1.2
Warrants to purchase shares | shares		400,000
Kind Therapeutics USA Inc. [Member]
Business Acquisition [Line Items]
Percentage of interests acquired in business acquisition						100.00%
Equity onwership percentage							70.00%
Payment for business acquisition | $			$ 6.3
Stock issued during period, shares, acquisitions | shares			2,500,000
Lessor, operating lease, term of contract			20 years
Area of land | ft²			180,000
Kind Therapeutics USA Inc. [Member] | Anne Arundel County, MD [Member]
Business Acquisition [Line Items]
Area of land | ft²					9,000
Meditaurus LLC [Member]
Business Acquisition [Line Items]
Equity onwership percentage	70.00%
Payment for business acquisition | $	$ 2.8
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method				The Company currently sells CBD products developed by MediTaurus under its Florance™ brand, and expects to acquire the remaining 30% of MediTaurus in 2021.

SCHEDULE OF INVESTMENTS (Detail

SCHEDULE OF INVESTMENTS (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Aug. 31, 2018
Schedule of Investments [Line Items]
Total investments	$ 2,107,698	$ 2,522,981
MembersRSVP LLC [Member]
Schedule of Investments [Line Items]
Non-current investments	1,165,788	1,165,788
Total investments			$ 300,000
Flowr Corp. (Formerly Terrace Inc.) [Member]
Schedule of Investments [Line Items]
Current investments	$ 941,910	$ 1,357,193

INVESTMENTS (Details Narrative)

INVESTMENTS (Details Narrative) - USD ($)	1 Months Ended			6 Months Ended
	Jan. 31, 2021	Dec. 31, 2020	Aug. 31, 2018	Jun. 30, 2021	Jun. 30, 2020
Acquired Indefinite-lived Intangible Assets [Line Items]
Investments		$ 2,522,981		$ 2,107,698
Number of common stock issued, value
MembersRSVP LLC [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Investments			$ 300,000
Number of common stock issued during period			378,259
Number of common stock issued, value			$ 915,000
Ownership percentage	12.00%		23.00%
Gain (Loss) on Sale of Equity Investments					33,000
Membership interest transferred	11.00%
Flowr Corp. (Formerly Terrace Inc.) [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Percentage for acquired interest rate		8.95%
Number of shares received under acquisition		0.4973
Change in fair value of investments				$ 415,000	$ 664,000

SCHEDULE OF FUTURE MINIMUM RENT

SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON-CANCELABLE LEASES AND SUBLEASES (Details)	Jun. 30, 2021USD ($)
Deferred Rents Receivable
2021	$ 2,411,711
2022	4,740,130
2023	4,446,410
2024	4,506,585
2025	4,574,023
Thereafter	39,591,553
Total	$ 60,270,412

DEFERRED RENTS RECEIVABLE (Deta

DEFERRED RENTS RECEIVABLE (Details Narrative) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)ft²	Dec. 31, 2020USD ($)	Jan. 31, 2017ft²	Sep. 30, 2016ft²
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land	300,000
Operating Lease, Lease Income | $	$ 16.3	$ 13.9
Contract with Customer, Liability, Revenue Recognized | $	18.1	15.8
Loans and Leases Receivable, Deferred Income | $	$ 1.8	$ 1.9
DELAWARE
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land	100,000			45,000
Lease expiration description	expires in 2035
DELAWARE | Retails Space [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land	4,000
Lessor, operating lease, option to extend	lease expiring in December 2021 with a five-year option to extend
DELAWARE | Cultivation and Processing Facility [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land	100,000
Lessor, operating lease, option to extend	The lease expires in March 2030, with an option to extend the term for three additional five-year periods
DELAWARE | Cannabis Production Facility [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land	12,000
Lessor, operating lease, option to extend	The lease expires in January 2026 and contains an option to negotiate an extension at the end of the lease term
MARYLAND
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land			180,000
Lease expiration description	expires in 2037
MASSACHUSETTS
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land	10,000
Lease expiration description	expiring in 2028
MASSACHUSETTS | Non-Cannabis [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land	138,000
Lease expiration description	expires in 2022

SCHEDULE OF NOTES RECEIVABLE (D

SCHEDULE OF NOTES RECEIVABLE (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Entity Listings [Line Items]
Total notes receivable	$ 1,571,575	$ 1,623,130
Notes receivable, current portion	377,127	658,122
Notes receivable, less current portion	1,194,448	965,008
First State Compassion Center [Member]
Entity Listings [Line Items]
Total notes receivable	437,014	468,985
Healer LLC [Member]
Entity Listings [Line Items]
Total notes receivable	879,642	899,226
High Fidelity Inc [Member]
Entity Listings [Line Items]
Total notes receivable	$ 254,919	$ 254,919

NOTES RECEIVABLE (Details Narra

NOTES RECEIVABLE (Details Narrative) - USD ($)	1 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	May 31, 2016	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Dec. 30, 2020	Aug. 31, 2019
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from notes receivable				$ 118,811	$ 406,670
Notes Receivable, Related Parties, Current	$ 377,127			377,127				$ 658,122
Financing Receivable, after Allowance for Credit Loss, Current	377,127			377,127				658,122
Promissory Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount	880,000			880,000	$ 352,000				$ 899,000
Financing Receivable, after Allowance for Credit Loss, Current	52,000			52,000					$ 337,000
Healer [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount		$ 894,000
Delaware Cannabis-licensee [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Term			10 years
Proceeds from notes receivable			$ 700,000
Interest rate			12.50%
Debt Instrument, Periodic Payment			$ 10,000
Notes Receivable, Related Parties, Current	$ 70,000			$ 70,000				$ 66,000
Healer LLC [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Interest rate		6.00%
Debt instrument, maturity date, description	requires quarterly payments of interest from April 2021 through the maturity date in April 2026
Healer LLC [Member] | Dr. Dustin Sulak [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from notes receivable						$ 800,000	$ 800,000
Interest rate						6.00%	6.00%
Healer LLC [Member] | Healer [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount		$ 866,000
Licensing fees		$ 28,000
High Fidelity Inc [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Interest rate										10.00%
Due to related parties										$ 250,000
Maryland Health and Wellness Center Inc. [Member] | Construction Loan [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Interest rate						8.00%
Due to related parties						$ 300,000

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Plants	$ 3,570,394	$ 3,352,425
Ingredients and other raw materials	245,353	176,338
Work-in-process	326,095	468,377
Finished goods	5,086,256	2,833,431
Total inventory	$ 9,228,098	$ 6,830,571

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 58,500,981	$ 50,525,251
Less: accumulated depreciation	(5,834,949)	(4,888,722)
Property and equipment, net	52,666,031	45,636,529
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	3,988,810	3,988,810
Buildings and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	31,187,512	29,309,856
Tenant Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	9,044,543	8,844,974
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	796,742	619,880
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	6,058,423	4,620,924
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 7,424,950	$ 3,140,807

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Entity Listings [Line Items]
Property, Plant and Equipment, Additions	$ 7,976,000	$ 1,876,000
Depreciation	962,571		$ 907,285
Milford, DE and Annapolis, MD [Member]
Entity Listings [Line Items]
Construction in Progress, Gross	$ 7,400,000	$ 3,100,000

INTANGIBLES (Details Narrative)

INTANGIBLES (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 2,100,000	$ 2,100,000
Cannabis Licenses [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 453,000	$ 161,000

SCHEDULE OF MORTGAGES PAYABLE (

SCHEDULE OF MORTGAGES PAYABLE (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total mortgages payable	$ 17,859,327
Mortgage [Member]
Short-term Debt [Line Items]
Total mortgages payable	15,834,803	$ 16,131,150
Mortgages payable, current portion	(1,350,548)	(1,387,014)
Mortgages payable, less current portion	14,484,255	14,744,136
Mortgage [Member] | Bank of New England - Massachusetts Property [Member]
Short-term Debt [Line Items]
Total mortgages payable	12,665,790	12,834,090
Mortgage [Member] | Bank of New England - Delaware Property [Member]
Short-term Debt [Line Items]
Total mortgages payable	1,519,716	1,575,658
Mortgage [Member] | DuQuoin State Bank - Illinois Properties [Member]
Short-term Debt [Line Items]
Total mortgages payable	793,733	814,749
Mortgage [Member] | South Porte Bank - Illinois Property [Member]
Short-term Debt [Line Items]
Total mortgages payable	$ 855,564	$ 906,653

SCHEDULE OF AGGREGATE MATURITIE

SCHEDULE OF AGGREGATE MATURITIES OF DEBT OUTSTANDING (Details)	Jun. 30, 2021USD ($)
Debt Disclosure [Abstract]
2021	$ 1,151,743
2022	521,091
2023	2,516,622
2024	588,520
2025	629,384
Thereafter	12,504,018
Total	17,911,377
Less discounts	(52,050)
Long-term debt, net	$ 17,859,327

DEBT (Details Narrative)

DEBT (Details Narrative)	Oct. 31, 2020USD ($)$ / sharesshares	Oct. 31, 2020USD ($)$ / sharesshares	Jul. 31, 2020USD ($)	Feb. 29, 2020USD ($)	May 02, 2019	Jun. 30, 2021USD ($)ft²$ / shares	Apr. 30, 2021USD ($)$ / shares	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / shares	Oct. 31, 2020USD ($)$ / sharesshares	Aug. 31, 2020	Jul. 31, 2020USD ($)	Jun. 30, 2020USD ($)$ / sharesshares	Apr. 30, 2020USD ($)	Feb. 29, 2020USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Apr. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Nov. 30, 2017USD ($)ft²	May 31, 2016ft²	Jun. 30, 2021USD ($)ft²$ / sharesshares	Mar. 31, 2021USD ($)$ / shares	Jun. 30, 2021USD ($)ft²$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)	Dec. 30, 2020USD ($)	Mar. 30, 2019USD ($)	Sep. 30, 2016ft²
Debt Instrument [Line Items]
Area of Land | ft²						300,000																300,000		300,000
Proceeds from Notes Payable																								$ 35,096	$ 5,249,763
Repayments of Notes Payable																								15,801,979	3,100,000
Debt instrument converted amount																								2,259,791	460,050
Payments of Stock Issuance Costs	$ 100,000																							386,983
Notes Payable, Current						$ 9,523			$ 8,859,175													$ 9,523		$ 9,523			$ 8,859,175
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 0.11																$ 0.11		$ 0.11
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 5.50																$ 5.50		$ 5.50
8.8M Note [Member]
Debt Instrument [Line Items]
Debt instrument converted shares | shares								3,365,972
Debt Instrument, Periodic Payment												$ 4,000,000
Additional principal payment			$ 600,000									600,000
Debt principal amount, current								$ 3,200,000	4,200,000														$ 3,200,000				4,200,000
Debt Instrument, Convertible, Conversion Price | $ / shares								$ 0.30															$ 0.30
Debt instrument converted amount								$ 1,000,000
Accrued interest								10,000															$ 10,000
3.2M [Member]
Debt Instrument [Line Items]
Debt instrument converted shares | shares																						3,571,428
Debt principal amount, current						$ 1,960,000																$ 1,960,000		$ 1,960,000
Debt instrument converted amount																						1,250,000
1M Note [Member]
Debt Instrument [Line Items]
Debt principal amount, current									$ 500,000																		$ 500,000
Secured Promissory Notes [Member] | 6M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																		13.00%
Interest and Debt Expense																												$ 300,000
Notes Issued																		$ 6,000,000
Debt instrument, extended maturity description																		The $6M Note’s initial maturity date of December 31, 2019 was extended to April 2020
Debt Instrument, Fee Amount																														$ 900,000
Secured Promissory Notes [Member] | 3M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																			10.00%
Debt maturity date description																			March 2020
Fair Value Adjustment of Warrants																			$ 1,511,000
Notes Issued																			$ 3,000,000
Debt instrument, extended maturity description																			extended for an additional six months in accordance with its terms, with the interest rate increasing to 12% per annum during the extension period. Pursuant to the Initial Extension Agreement, the maturity date of the $3M Note was extended to December 2020
Promissory Note [Member]
Debt Instrument [Line Items]
Debt instrument converted shares | shares													2,525,596
Debt Instrument, Periodic Payment													$ 460,050
Promissory Note [Member] | 11.5M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 11,500,000											$ 11,500,000
Debt Instrument, Interest Rate During Period				15.00%
Debt maturity date description				maturing in June 2020
Promissory Note [Member] | 11.5M Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)				$ 3,000,000
Promissory Note [Member] | 5.8M Note [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)																							450,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 880,000							$ 352,000									$ 880,000		$ 880,000	352,000				$ 899,000
Debt instrument converted shares | shares													1,900,000											6,937,400
Promissory Notes [Member] | Individuals and Accredited Investors [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 0.32																		$ 0.32
Promissory Notes [Member] | Minimum [Member] | Individuals and Accredited Investors [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																											6.50%
Promissory Notes [Member] | Maximum [Member] | Individuals and Accredited Investors [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																											18.00%
Promissory Notes [Member] | 3M Note [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																			750,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																			$ 1.80
Existing Notes [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable																											$ 500,000
Notes Payable, Fair Value Disclosure									$ 3,190,000																		3,190,000
Existing Notes [Member] | Individuals and Accredited Investors [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable																											2,100,000
New 2020 Notes [Member] | Individuals and Accredited Investors [Member]
Debt Instrument [Line Items]
Proceeds from Notes Payable																											2,147,000
Repayments of Notes Payable																											$ 700,000
New 2020 Notes [Member] | Minimum [Member] | Individuals and Accredited Investors [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																											12.00%
New 2020 Notes [Member] | Maximum [Member] | Individuals and Accredited Investors [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																											15.00%
Existing Notes and New 2020 Notes [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable																											$ 200,000
Notes Payable, Fair Value Disclosure									2,037,000																		2,037,000
MariMed Hemp Inc. [Member] | Secured Promissory Notes [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable									500,000
MariMed Hemp Inc. [Member] | Secured Promissory Notes [Member] | 10M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount																$ 10,000,000
Debt maturity date description																maturity date of January 31, 2020
Repayments of Notes Payable																$ 1,500,000
[custom:WarrantsAndRightsOutstandingTermDescription]																three-year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 4.50
Fair Value Adjustment of Warrants																$ 601,000
Interest and Debt Expense																												$ 523,000
MariMed Hemp Inc. [Member] | Secured Promissory Notes [Member] | 1M Note [Member] | GenCanna [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount																	$ 1,000,000
MariMed Hemp Inc. [Member] | Secured Promissory Notes [Member] | 1M Note [Member] | Note Holder [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																	15.00%
Repayments of Notes Payable																	$ 30,000
DELAWARE
Debt Instrument [Line Items]
Area of Land | ft²						100,000																100,000		100,000							45,000
Mortgage Agreement [Member]
Debt Instrument [Line Items]
Agreement term																				10 years
Mortgage Agreement [Member] | DuQuoin State Bank [Member]
Debt Instrument [Line Items]
Area of Land | ft²																					3,400
Debt Instrument, Face Amount						$ 793,000			815,000													$ 793,000		$ 793,000			815,000
Debt Instrument, Interest Rate During Period																					6.75%
Debt principal amount, current						32,000			31,000													32,000		32,000			31,000
Mortgage Agreement [Member] | South Porte Bank [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period															5.50%
Debt Instrument, Maturity Date				Aug. 31, 2021
Mortgage Agreement [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate					2.00%															2.00%
Mortgage Agreement [Member] | Floor Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate					6.25%															6.25%
Mortgage Agreement [Member] | New Bedford, Massachusetts [Member]
Debt Instrument [Line Items]
Debt instrument, face amount																				$ 4,895,000
Area of Land | ft²																				138,000
[custom:AreaOfLandCultivatingAndProcessingFacility-0] | ft²																				70,000
Debt Instrument, Face Amount																				$ 4,800,000
Mortgage Agreement [Member] | DELAWARE
Debt Instrument [Line Items]
Area of Land | ft²																				45,070
Debt Instrument, Face Amount						1,500,000			1,600,000													1,500,000		1,500,000			1,600,000
Debt maturity date description																				mortgage matures in 2031
Debt principal amount, current						117,000			114,000													117,000		117,000			114,000
Mortgage Agreement [Member] | DELAWARE | September 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																				5.25%
Mortgage Agreement [Member] | DELAWARE | Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																				1.50%
Mortgage Agreement [Member] | DELAWARE | Floor Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period																				5.25%
Refinanced Mortgage [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 13,000,000			12,700,000			12,800,000			13,000,000										12,700,000		12,700,000			12,800,000
Debt Instrument, Interest Rate During Period			6.50%
Debt maturity date description			matures in August 2025
Proceeds from Notes Payable			$ 7,200,000
Debt principal amount, current						346,000			335,000													346,000		346,000			335,000
Exchange Agreement [Member] | 4.4 Million Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period															16.50%
Debt maturity date description															maturing in August 2021
Exchange Agreement [Member] | 4.4 Million Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 4,400,000					4,600,000						$ 4,400,000												4,600,000
Second Amendment Agreement [Member] | 11.5M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount													$ 352,000												352,000
Debt instrument converted shares | shares													1,900,000
Second Amendment Agreement [Member] | 8.8M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount													$ 8,800,000												$ 8,800,000
Debt Instrument, Interest Rate During Period													15.00%
Debt maturity date description													maturing in June 2022
[custom:WarrantsAndRightsOutstandingTermDescription]													three-year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares													750,000												750,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.50												$ 0.50
Fair Value Adjustment of Warrants													$ 66,000
Extension fees																										$ 330,000,000,000
Third Amendment Agreement [Member] | 3.2M [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period							0.12%
Third Amendment Agreement [Member] | Restated Promissory Note [Member] | 3.2M [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount							$ 3,200,000
Debt maturity date description							matures in April 2023
Debt Instrument, Convertible, Conversion Price | $ / shares							$ 0.35
Percentage of prepayment debt							0.10
Redemption of principal and unpaid interest							$ 125,000
Third Amendment Agreement [Member] | Promissory Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period		12.00%
Debt instrument, extended maturity description		maturity dates in September 2022
GenCanna [Member] | MariMed Hemp Inc. [Member] | Secured Promissory Notes [Member] | 1M Note [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable																	$ 180,000
Hadron Healthcare Master Fund [Member] | Secured Promissory Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount								$ 500,000															$ 500,000
Extension Agreement [Member]
Debt Instrument [Line Items]
Debt instrument converted shares | shares													2,525,596
Extension Agreement [Member] | 6M Note [Member]
Debt Instrument [Line Items]
Accrued interest														$ 845,000
Debt Conversion, Converted Instrument, Rate														10.00%
Extension Agreement [Member] | 900K Note [Member]
Debt Instrument [Line Items]
Accrued interest														$ 20,100
Payment of service fee														$ 900,000
Debt Conversion, Converted Instrument, Rate														12.00%
Service fees payment														$ 900
Principal and accrued interest			$ 460,050									$ 460,050
Second Extension Agreement [Member] | Promissory Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount									8,300,000																		8,300,000
Debt principal amount, current									1,900,000																		1,900,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	5,000,000	5,000,000								5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.25	$ 0.25								$ 0.25
Interest and Debt Expense										$ 573,000
Amortization of Debt Discount (Premium)										75,000
Second Extension Agreement [Member] | Promissory Notes [Member] | 6.8M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,000,000	$ 1,000,000								1,000,000
Interest and Debt Expense		333,000
Second Extension Agreement [Member] | Promissory Notes [Member] | 5.8M Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 5,845,000	$ 5,845,000								5,845,000
Second Extension Agreement [Member] | February 2021 [Member] | Promissory Notes [Member] | 5.8M Note [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable										$ 400,000
First Citizens Federal Credit Union [Member] | Promissory Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period		5.74%
Debt maturity date description											matures in July 2026
Notes Payable						28,000			30,000													28,000		28,000			30,000
Notes Payable, Current						$ 5,000			$ 5,000													5,000		5,000			$ 5,000
Note Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period						10.00%
Debt maturity date description						matures in May 2027
Notes Payable						$ 35,000																35,000		35,000
Notes Payable, Current						$ 5,000																$ 5,000		$ 5,000

SCHEDULE OF DEBENTURE TRANSACTI

SCHEDULE OF DEBENTURE TRANSACTION (Details)	6 Months Ended
	Jun. 30, 2021USD ($)shares
Convertible Debentures One [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Issuance Date	Oct. 17, 2018
Debt Instrument, Maturity Date	Oct. 16, 2020
Debt Instrument, Face Amount	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	1.00%
Warrant discount	$ 457,966
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 1,554,389
Debt Conversion, Converted Instrument, Shares Issued | shares	5,000,000
Convertible Debentures Two [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Issuance Date	Nov. 7, 2018
Debt Instrument, Maturity Date	Nov. 6, 2020
Debt Instrument, Face Amount	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	1.00%
Warrant discount	$ 599,867
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 4,015,515
Debt Conversion, Converted Instrument, Shares Issued | shares	5,000,000
Convertible Debentures Three [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Issuance Date	May 8, 2019
Debt Instrument, Maturity Date	May 7, 2021
Debt Instrument, Face Amount	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	1.00%
Warrant discount	$ 783,701
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 2,537,235
Debt Conversion, Converted Instrument, Shares Issued | shares	5,000,000
Convertible Debentures Four [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Issuance Date	Jun. 28, 2019
Debt Instrument, Maturity Date	Jun. 27, 2021
Debt Instrument, Face Amount	$ 2,500,000
Debt Instrument, Interest Rate, Stated Percentage	0.00%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	7.00%
Warrant discount	$ 145,022
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 847,745
Debt Conversion, Converted Instrument, Shares Issued | shares	2,500,000
Convertible Debentures Five [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Issuance Date	Aug. 20, 2019
Debt Instrument, Maturity Date	Aug. 19, 2021
Debt Instrument, Face Amount	$ 2,500,000
Debt Instrument, Interest Rate, Stated Percentage	0.00%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	7.00%
Warrant discount	$ 219,333
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 850,489
Debt Conversion, Converted Instrument, Shares Issued | shares	2,500,000
Convertible Debentures Six [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Issuance Date	Feb. 21, 2020
Debt Instrument, Maturity Date	Feb. 20, 2021
Debt Instrument, Face Amount	$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.50%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	6.50%
Warrant discount	$ 28,021
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 379,183
Debt Conversion, Converted Instrument, Shares Issued | shares	1,000,000

DEBENTURES PAYABLE (Details Nar

DEBENTURES PAYABLE (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Feb. 29, 2020
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Amortization of original issue discount			$ 51,753	$ 241,613
Interest Expense	$ 264,596	$ 2,969,191	1,776,618	$ 5,660,336
21M Debentures Holder [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Face Amount					$ 1,300,000
Unamortized balances of the beneficial conversion feature					177,000
Unamortized balance of warrants discount					39,000
Unamortized balance of original issue discount					52,000
Debt Instrument, Fair Value Disclosure					1,032,000
Convertible Debentures [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Face Amount	1,300,000		1,300,000		9,700,000
Interest Payable	$ 56,000		$ 56,000		$ 365,000
Debt Conversion, Converted Instrument, Shares Issued			4,610,645		77,766,559
Debt Instrument, Convertible, Conversion Price	$ 0.29		$ 0.29
Amortization			$ 177,000		$ 3,200,000
Amortization of the warrants discount			39,000		805,000
Amortization of original issue discount			52,000		321,000
Interest Expense			$ 1,000		$ 224,000
Convertible Debentures [Member] | Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 0.11
Convertible Debentures [Member] | Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Convertible, Conversion Price					0.34
Convertible Debentures [Member] | 21M Debentures Holder [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Face Amount						$ 21,000,000
Equity Method Investment, Ownership Percentage	80.00%		80.00%
Debt Instrument, Convertible, Conversion Price					$ 0.75
Warrant term					P3Y
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					180,000
Fair Value Adjustment of Warrants			$ 2,200,000
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 10,200,000
Convertible Debentures [Member] | 21M Debentures Holder [Member] | Warrants [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,354,675
Convertible Debentures [Member] | 21M Debentures Holder [Member] | Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Equity Method Investment, Ownership Percentage	4.99%		4.99%
Convertible Debentures [Member] | 21M Debentures Holder [Member] | Minimum [Member] | Warrants [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 0.75
Convertible Debentures [Member] | 21M Debentures Holder [Member] | Maximum [Member] | Warrants [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 5.50
Convertible Debentures [Member] | Holder [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Face Amount	$ 21,000,000		$ 21,000,000
Interest Payable	$ 836,000		$ 836,000
Debt Conversion, Converted Instrument, Shares Issued			92,704,035
Convertible Debentures [Member] | Holder [Member] | Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 0.11		$ 0.11
Convertible Debentures [Member] | Holder [Member] | Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 3.06		$ 3.06

MEZZANINE EQUITY (Details Narra

MEZZANINE EQUITY (Details Narrative) - USD ($)	Feb. 29, 2020	Mar. 31, 2021	Feb. 29, 2020	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Entity Listings [Line Items]
Stock Issued During Period, Value, New Issues
Proceeds from Issuance or Sale of Equity		$ 23,000,000
Payments for Construction in Process		$ 7,800,000
Company owned and managed facilities during period					$ 6,600,000
Targeted acquisition commitment description		The balance of the committed facility of up to an additional $23.0 million is intended to fund the Company’s specific targeted acquisitions provided such acquisitions are contracted in 2021 and consummated, including obtaining the necessary regulatory approvals, no later than the end of 2022
Warrants Two [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					15,540,540
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.087
Fair Value Adjustment of Warrants				$ 9,500,000	$ 9,500,000
Maximum [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5.50
Minimum [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.11
Hadron Healthcare Master Fund [Member] | Warrants [Member]
Entity Listings [Line Items]
Number of common stock issued during period		6,216,216
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.087		$ 1.087
Stock issuance costs		$ 387,000
Hadron Healthcare Master Fund [Member] | Maximum [Member] | Warrants [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		15,540,540		15,540,540
3M Note [Member]
Entity Listings [Line Items]
Repayments of Debt and Lease Obligation					$ 15,200,000
Series B Convertible Preferred Stock [Member] | Volume Weighted Average Price of Common Stock [Member]
Entity Listings [Line Items]
Preferred Stock, Convertible, Conversion Price	$ 4		$ 4
Number of trading days, description			least twenty consecutive trading days
Series B preferred stock conversion price, description	If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option		If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share.
Series B Holders [Member]
Entity Listings [Line Items]
Shares Issued, Price Per Share	$ 3		$ 3
Preferred Stock, Convertible, Conversion Price	3		$ 3
Series C Convertible Preferred Stock [Member] | Minimum [Member]
Entity Listings [Line Items]
Outstanding percentage.		50.00%
Exchange Agreement [Member] | Two Institutional Shareholders [Member] | Series B Convertible Preferred Stock [Member]
Entity Listings [Line Items]
Stock Issued During Period Shares Exchanged			4,908,333
Shares Issued, Price Per Share	$ 3		$ 3
Treasury Stock Acquired, Average Cost Per Share			$ 3
Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member]
Entity Listings [Line Items]
Shares Issued, Price Per Share		$ 3.70		$ 3.70
Stock Issued During Period, Value, New Issues		$ 23,000,000
Warrants and Rights Outstanding, Term		4 years		4 years
Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member] | Maximum [Member]
Entity Listings [Line Items]
Number of shares exchanged value.		$ 46,000,000

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Feb. 29, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 30, 2020
Class of Stock [Line Items]
Additional paid in capital			$ 117,919,783		$ 117,919,783		$ 112,974,329
Non-cash losses on debt settlement			1,260	$ 44,678	2,546	$ 44,678
Stock Issued During Period, Value, New Issues
Previously Issued Subscription [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues					11,413	3,236,857
Stock Issued During Period, Value, New Issues					$ 5,000	$ 1,168,000
Promissory Notes [Member]
Class of Stock [Line Items]
Conversion of promissory notes, shares	1,900,000				6,937,400
Debt Conversion, Original Debt, Amount					$ 2,260,000
Debt principal amount	$ 352,000		880,000	$ 352,000	$ 880,000	$ 352,000		$ 899,000
Promissory Note [Member]
Class of Stock [Line Items]
Conversion of promissory notes, shares	2,525,596
Debt Instrument, Periodic Payment	$ 460,050
21M Debentures Holder [Member]
Class of Stock [Line Items]
Conversion of promissory notes, shares					4,610,645		77,766,559
Debt principal amount			$ 1,400,000		$ 1,400,000		$ 10,100,000
Common Stock [Member]
Class of Stock [Line Items]
Number of shares granted					6,877	64,478
Number of stock options granted, value					$ 5,000	$ 11,000
Non-cash losses on debt settlement					$ 2,500	$ 45,000
Common Stock Subscribed But Not Issued [Member]
Class of Stock [Line Items]
Number of shares granted						34,171
Fair value of granted						$ 5,000
Stock Issued During Period, Shares, New Issues					(11,413)	(3,236,857)
Stock Issued During Period, Value, New Issues					$ (5,365)	$ (1,168,074)
Common Stock [Member]
Class of Stock [Line Items]
[custom:CommonStockIssuedToSettleObligationsShares]					71,691	4,400,000
Common stock issued to settle obligations					$ 51,000	$ 699,000
Stock Issued During Period, Shares, New Issues					11,413	3,236,857
Stock Issued During Period, Value, New Issues					$ 11	$ 3,237
Conversion of promissory notes, shares					6,937,400	2,525,596
Number of shares options exercised					82,885
Options [Member]
Class of Stock [Line Items]
Number of shares options exercised					82,885	0
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					698,812	0
Common Stock Issuance Obligations [Member]
Class of Stock [Line Items]
Number of shares granted						34,171
Number of stock options granted, value						$ 5,000
Exchange Agreement [Member] | Two Institutional Shareholders [Member] | Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of common stock exchanged during period		4,908,333
Treasury stock, preferred, value		$ 14,725,000
Shares issued, price per share		$ 3
Treasury stock, common, value		$ 5,000
Additional paid in capital		$ 14,720,000

SCHEDULE OF STOCK OPTIONS OUTST

SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding shares under option	12,402,750
Exercisable shares under option	8,374,625
Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.140
Outstanding shares under option	160,000
Exercisable shares under option	40,000
Remaining Life in Years	4 years 10 days
Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.149
Outstanding shares under option	500,000
Exercisable shares under option	500,000
Remaining Life in Years	4 years 6 months 3 days
Range Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.169
Outstanding shares under option	200,000
Exercisable shares under option	200,000
Remaining Life in Years	4 years 4 months 13 days
Range Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.210
Outstanding shares under option	70,000
Exercisable shares under option	50,000
Remaining Life in Years	4 years 4 months 24 days
Range Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.225
Outstanding shares under option	2,000,000
Exercisable shares under option	1,062,500
Remaining Life in Years	4 years 4 months 9 days
Range Six [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Outstanding shares under option	20,000
Exercisable shares under option	20,000
Remaining Life in Years	3 years 11 months 1 day
Range Seven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Outstanding shares under option	50,000
Exercisable shares under option	12,500
Remaining Life in Years	4 years 3 months 25 days
Range Eight [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Outstanding shares under option	800,000
Exercisable shares under option	400,000
Remaining Life in Years	4 years 4 months 13 days
Range Nine [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Outstanding shares under option	80,000
Exercisable shares under option	40,000
Remaining Life in Years	4 years 4 months 24 days
Range Ten [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Outstanding shares under option	50,000
Exercisable shares under option	50,000
Remaining Life in Years	3 years 8 months 1 day
Range Eleven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.300
Outstanding shares under option	524,500
Exercisable shares under option	262,250
Remaining Life in Years	3 years 9 months
Range Twelve [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.417
Outstanding shares under option	900,000
Exercisable shares under option	900,000
Remaining Life in Years	3 years 5 months 26 days
Range Thirteen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.505
Outstanding shares under option	100,000
Exercisable shares under option	25,000
Remaining Life in Years	4 years 6 months 7 days
Range Fourteen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.505
Outstanding shares under option	800,000
Exercisable shares under option	100,000
Remaining Life in Years	4 years 6 months 10 days
Range Fifteen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.590
Outstanding shares under option	15,000
Exercisable shares under option	15,000
Remaining Life in Years	3 years 5 months 8 days
Range Sixteen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.630
Outstanding shares under option	300,000
Exercisable shares under option	300,000
Remaining Life in Years	6 months
Range Seventeen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.740
Outstanding shares under option	590,000
Exercisable shares under option	338,125
Remaining Life in Years	4 years 9 months 29 days
Range Eighteen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.770
Outstanding shares under option	200,000
Exercisable shares under option	200,000
Remaining Life in Years	1 year 6 months
Range Nineteen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.830
Outstanding shares under option	287,000
Exercisable shares under option	71,750
Remaining Life in Years	4 years 8 months 23 days
Range Twenty [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.830
Outstanding shares under option	600,000
Exercisable shares under option
Remaining Life in Years	4 years 10 months 28 days
Range Twenty One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.850
Outstanding shares under option	90,000
Exercisable shares under option	25,000
Remaining Life in Years	4 years 11 months 15 days
Range Twenty Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.890
Outstanding shares under option	10,000
Exercisable shares under option
Remaining Life in Years	4 years 6 months 21 days
Range Twenty Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.892
Outstanding shares under option	40,000
Exercisable shares under option	10,000
Remaining Life in Years	4 years 6 months 21 days
Range Twenty Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.895
Outstanding shares under option	25,000
Exercisable shares under option	6,250
Remaining Life in Years	4 years 6 months 25 days
Range Twenty Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.900
Outstanding shares under option	50,000
Exercisable shares under option	50,000
Remaining Life in Years	1 year 10 months 9 days
Range Twenty Six [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.910
Outstanding shares under option	50,000
Exercisable shares under option	50,000
Remaining Life in Years	1 year 3 months 21 days
Range Twenty Seven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.950
Outstanding shares under option	50,000
Exercisable shares under option	50,000
Remaining Life in Years	1 year 6 months
Range Twenty Eight [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.970
Outstanding shares under option	100,000
Exercisable shares under option	25,000
Remaining Life in Years	4 years 11 months 15 days
Range Twenty Nine [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.983
Outstanding shares under option	145,000
Exercisable shares under option
Remaining Life in Years	4 years 11 months 26 days
Range Thirty [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.992
Outstanding shares under option	300,000
Exercisable shares under option	300,000
Remaining Life in Years	3 years 2 months 26 days
Range Thirty One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1
Outstanding shares under option	15,000
Exercisable shares under option	15,000
Remaining Life in Years	2 years 11 months 15 days
Range Thirty Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1
Outstanding shares under option	125,000
Exercisable shares under option	125,000
Remaining Life in Years	3 years 4 months 2 days
Range Thirty Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1.350
Outstanding shares under option	100,000
Exercisable shares under option	75,000
Remaining Life in Years	2 years 29 days
Range Thirty Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1.950
Outstanding shares under option	375,000
Exercisable shares under option	375,000
Remaining Life in Years	2 years
Range Thirty Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.320
Outstanding shares under option	100,000
Exercisable shares under option	100,000
Remaining Life in Years	2 years 2 months 12 days
Range Thirty Six [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.450
Outstanding shares under option	2,000,000
Exercisable shares under option	2,000,000
Remaining Life in Years	1 year 5 months 23 days
Range Thirty Seven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.500
Outstanding shares under option	100,000
Exercisable shares under option	100,000
Remaining Life in Years	2 years 1 month 28 days
Range Thirty Eighteen [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.650
Outstanding shares under option	200,000
Exercisable shares under option	200,000
Remaining Life in Years	2 years 2 months 26 days
Range Thirty Nine [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.850
Outstanding shares under option	56,250
Exercisable shares under option	56,250
Remaining Life in Years	1 year 5 months 12 days
Range Fourty [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.850
Outstanding shares under option	100,000
Exercisable shares under option	100,000
Remaining Life in Years	2 years 5 months 12 days
Range Fourty One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 3
Outstanding shares under option	25,000
Exercisable shares under option	25,000
Remaining Life in Years	2 years 5 months 15 days
Range Fourty Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 3.725
Outstanding shares under option	100,000
Exercisable shares under option	100,000
Remaining Life in Years	2 years 5 months 8 days

STOCK OPTIONS (Details Narrativ

STOCK OPTIONS (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Exercised Cashless Shares	125,000
Exercise paid surrender shares of common stock	72,115
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.30
Fair value of options granted	$ 1,458,000	$ 67,000
Amortized fair value of options granted	704,000	25,000
Share-based Payment Arrangement, Expense	$ 180,000	$ 549,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	50,000	30,000
Amortization	$ 0	$ 19,000
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.30
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,802,000	564,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	155,000
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.30
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.45

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Debenture Payable [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			180,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.75
Warrants and Rights Outstanding, Term			3 years
Fair Value Adjustment of Warrants			$ 94,000
Proceeds from Issuance of Warrants			$ 20,000
Eight Point Eight Million [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			750,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50
Minimum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.11
Maximum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.50
Warrants One [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,100,000
Fair Value Adjustment of Warrants		$ 710,000
Warrants One [Member] | Minimum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.82
Warrants and Rights Outstanding, Term		3 years
Warrants One [Member] | Maximum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.83
Warrants and Rights Outstanding, Term		4 years
Warrants Two [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		15,540,540
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.087
Fair Value Adjustment of Warrants	$ 9,500,000	$ 9,500,000
Proceeds from Issuance of Warrants		$ 23,000,000
Warrant Exercised [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		956,250
Warrant Exercised [Member] | Minimum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.11
Warrant Exercised [Member] | Maximum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.55
Warrant Forfeited [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,426,500
Warrant Forfeited [Member] | Minimum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.90
Warrant Forfeited [Member] | Maximum [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.25
Common Stock [Member]
WarrantsAndRightsNoteDisclosureLineItems [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		29,174,958	12,710,107

SCHEDULE OF REVENUES COMPRISED

SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Total revenues	$ 57,212,220	$ 17,076,325
Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	35,776,191	9,942,804
Product Sales Wholesale [Member]
Disaggregation of Revenue [Line Items]
Total revenues	13,902,969
Real Estate [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,670,462	3,492,042
Management Service [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,877,407	748,696
Supply Procurement [Member]
Disaggregation of Revenue [Line Items]
Total revenues	918,018	818,900
License and Service [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,067,173	$ 796,847

REVENUES (Details Narrative)

REVENUES (Details Narrative)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Two Clients [Member]
Disaggregation of Revenue [Line Items]
Concentration Risk, Percentage	12.00%	30.00%

BAD DEBTS (Details Narrative)

BAD DEBTS (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
DebtLineItems [Line Items]
Provision for doubtful account	$ 1,819,000
A R Allowance [Member]
DebtLineItems [Line Items]
Accounts Receivable, Allowance for Credit Loss	1,400,000	$ 450,000
Increase in reserve working capital	$ 419,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	Dec. 31, 2020	Apr. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Transaction [Line Items]
Operating Lease, Expense			$ 78,000	$ 78,000
Payments to Acquire Property, Plant, and Equipment			$ 7,975,731	2,720,655
Due to other related parties	$ 1,200,000
Bettys Eddies Products [Member] | Royalty Agreement [Member]
Related Party Transaction [Line Items]
Changed in royalty percentage			2.50%
Royalty percentage description			(i) 3.0% and 10.0% of wholesale sales of existing products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively, and (ii) 0.5% and 1.0% of wholesale sales of future developed products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively.
Due to Affiliate			$ 162,000	$ 148,000
Common Stock [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			82,885
Options [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			82,885	0
COO [Member]
Related Party Transaction [Line Items]
Shares Issued, Price Per Share		$ 0.30
Fair value of options		$ 6,000
COO [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		50,000
CEO, CFO and Independent Board Member [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	550,000
CEO, CFO and Independent Board Member [Member] | Options [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Shares Issued, Price Per Share	$ 0.13
CEO, CFO and Independent Board Member [Member] | Options [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Shares Issued, Price Per Share	$ 0.14
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Payments to Acquire Property, Plant, and Equipment			$ 2,015,000	$ 1,141,000
CEO and CFO [Member]
Related Party Transaction [Line Items]
Payments to Acquire Additional Interest in Subsidiaries			21,000	19,000
Purchased fixed assets and consulting services			573,000	0
CEO and CFO [Member] | Owned Companies [Member]
Related Party Transaction [Line Items]
Due to other related parties	$ 653,000
Employee [Member]
Related Party Transaction [Line Items]
Payments to Acquire Property, Plant, and Equipment			$ 466,000	$ 145,000
CEO [Member]
Related Party Transaction [Line Items]
Due to other related parties	460,000
Stockholders [Member]
Related Party Transaction [Line Items]
Due to other related parties	$ 45,000

SCHEDULE OF COMPONENTS OF LEASE

SCHEDULE OF COMPONENTS OF LEASE EXPENSE (Details)	3 Months Ended
	Jun. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 543,593
Amortization of right-of-use assets	16,342
Interest on lease liabilities	2,855
Total finance lease cost	$ 19,197

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON-CANCELABLE OPERATING LEASES (Details)	Jun. 30, 2021USD ($)
Lessor, Lease, Description [Line Items]
Operating Leases, 2021	$ 2,411,711
Operating Leases, 2022	4,740,130
Operating Leases, 2023	4,446,410
Operating Leases, 2024	4,506,585
Operating Leases, 2025	4,574,023
Operating Leases, Thereafter	39,591,553
Operating Lease, Total lease payments	60,270,412
Operating Leases [Member]
Lessor, Lease, Description [Line Items]
Operating Leases, 2021	564,469
Operating Leases, 2022	1,071,079
Operating Leases, 2023	1,035,017
Operating Leases, 2024	963,589
Operating Leases, 2025	936,947
Operating Leases, Thereafter	3,468,041
Operating Lease, Total lease payments	8,039,142
Less: Operating Leases, Imputed Interest	(2,058,393)
Operating Leases	5,980,749
Financing Leases [Member]
Lessor, Lease, Description [Line Items]
Finance Lease, 2021	19,206
Finance Lease, 2022	27,123
Finance Lease, 2023	23,201
Finance Lease, 2024	3,229
Finance Lease, 2025
Finance Lease, Thereafter
Finance Lease, Total lease payments	72,759
Less: Finance Lease, imputed interest	(6,208)
Finance Lease	$ 66,551

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	1 Months Ended		6 Months Ended
	May 31, 2020USD ($)	Nov. 30, 2019USD ($)	Jun. 30, 2021USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 31, 2017ft²	Sep. 30, 2016ft²
Product Liability Contingency [Line Items]
Number of operating leases, description			six
Number of finance leases, description			four finance leases
Area of land			300,000
Agreement term description			An employment agreement which commenced in 2012 with Thomas Kidrin, the former CEO of the Company, which provided Mr. Kidrin with salary, car allowances, stock options, life insurance, and other employee benefits, was terminated by the Company in 2017
Accrued Liabilities, Current | $			$ 8,145,061	$ 3,621,269
Loss contingency, damages sought, value | $			5,400,000
OGGUSA Debtors [Member]
Product Liability Contingency [Line Items]
Bankruptcy claim filed | $	$ 33,600,000
Bankruptcy claim by court | $	$ 31,000,000
GenCanna Global Inc. [Member]
Product Liability Contingency [Line Items]
Equity onwership percentage					33.50%
Related party receivable | $					$ 29,000,000
Maryland Acquisition [Member]
Product Liability Contingency [Line Items]
Loss contingency, damages sought, value | $		$ 75,000
Terminated Employment Agreement [Member]
Product Liability Contingency [Line Items]
Accrued Liabilities, Current | $			$ 1,043,000	$ 1,043,000
Finance Lease Commitments [Member] | Machinery and Office Equipment [Member]
Product Liability Contingency [Line Items]
Lease expiration, description			expire in February 2022 through June 2024
Lease Commitments [Member]
Product Liability Contingency [Line Items]
Operating Lease, Weighted Average Remaining Lease Term			7 years 9 months 18 days
Finance Lease, Weighted Average Remaining Lease Term			2 years 4 months 24 days
Lease Commitments [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Weighted average discount rate for lease liabilities			7.50%
Lease Commitments [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Weighted average discount rate for lease liabilities			12.00%
DELAWARE
Product Liability Contingency [Line Items]
Area of land			100,000				45,000
Lease expiration, description			expires in 2035
DELAWARE | Cannabis Production Facility [Member]
Product Liability Contingency [Line Items]
Area of land			12,000
Lease expiration, description			expires in January 2026
DELAWARE | Three Additional Five-Year Periods [Member]
Product Liability Contingency [Line Items]
Lease expiration, description			The lease term is 10 years, with an option to extend the term for three additional five-year periods
Lease term			10 years
DELAWARE | Operating Lease Commitments [Member]
Product Liability Contingency [Line Items]
Area of land			4,000
Lease term, description			five-year lease that expires in December 2021 with a five-year option to extend
NEVADA
Product Liability Contingency [Line Items]
Area of land			10,000
Lease expiration, description			expiring in 2024
MASSACHUSETTS
Product Liability Contingency [Line Items]
Area of land			10,000
Lease expiration, description			expiring in 2028
Lease term			10 years
Lease extension option			option to extend the term for an additional five-year period
MARYLAND
Product Liability Contingency [Line Items]
Area of land						180,000
MARYLAND | Operating Lease Commitments [Member]
Product Liability Contingency [Line Items]
Area of land			2,700
Lease expiration, description			expires in July 2022

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jul. 02, 2021	Aug. 31, 2021	Jul. 31, 2021
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award			11,250,000
Option to purchase common stock exercised			85,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Purchase of Assets			750,000
Stock Issued During Period, Value, Purchase of Assets			$ 705,000
Options grant period			5 years
Adjusted shares returned upon conversion			79,815
Stock issued for services			300,000
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.21
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.30
Subsequent Event [Member] | Note Holder [Member] | 3.2M [Member]
Subsequent Event [Line Items]
Principal balance		$ 387,000
Stock Issued During Period, Shares, New Issues		1,104,725
Subsequent Event [Member] | Employees [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			5 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			100,000
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures			145,217
Subsequent Event [Member] | Employees [Member] | Minimum [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.84
Subsequent Event [Member] | Employees [Member] | Maximum [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.90
Subsequent Event [Member] | Independent Board Members [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award			900,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.88
Subsequent Event [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Agreement expiration date	2024-06
Percentage of annual bonuses	75.00%
Subsequent Event [Member] | Employment Agreement [Member] | Non-Qualified Stock Options [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Expiration date	2026-07
Subsequent Event [Member] | Employment Agreement [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	$ 350,000
Subsequent Event [Member] | Employment Agreement [Member] | Chief Executive Officer [Member] | Non-Qualified Stock Options [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	5,000,000
Subsequent Event [Member] | Employment Agreement [Member] | Chief Financial Officer [Member]
Subsequent Event [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	$ 325,000
Subsequent Event [Member] | Employment Agreement [Member] | Chief Financial Officer [Member] | Non-Qualified Stock Options [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	5,000,000
Subsequent Event [Member] | Employment Agreement [Member] | Chief Operating Officer [Member]
Subsequent Event [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	$ 300,000
Subsequent Event [Member] | Employment Agreement [Member] | Chief Operating Officer [Member] | Non-Qualified Stock Options [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,250,000
Subsequent Event [Member] | Metropolis Property [Member]
Subsequent Event [Line Items]
Asset Acquisition, Contingent Consideration, Liability			$ 1,600,000
Subsequent Event [Member] | DuQuoin State Bank [Member]
Subsequent Event [Line Items]
Asset Acquisition, Contingent Consideration, Liability			$ 2,700,000
Maturity date			2041-07
Debt Instrument, Interest Rate, Stated Percentage			6.25%
Subsequent Event [Member] | Mari Holdings Metropolis LLC [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			30.00%